<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://www.jimmunol.org">
<title>The Journal of Immunology current issue</title>
<link>http://www.jimmunol.org</link>
<description>The Journal of Immunology RSS feed -- current issue</description>
<prism:eIssn>1550-6606</prism:eIssn>
<prism:coverDisplayDate>Jul  1 2009 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>The Journal of Immunology</prism:publicationName>
<prism:issn>0022-1767</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/1?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/3?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/5?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/27?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/32?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/37?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/41?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/51?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/59?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/66?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/75?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/83?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/97?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/106?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/117?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/129?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/137?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/145?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/155?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/164?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/172?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/181?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/191?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/201?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/209?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/221?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/228?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/237?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/246?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/254?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/261?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/270?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/277?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/285?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/298?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/310?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/319?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/332?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/340?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/352?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/359?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/370?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/381?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/388?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/400?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/411?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/421?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/430?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/438?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/445?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/452?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/462?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/470?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/480?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/491?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/499?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/506?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/518?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/524?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/533?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/543?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/552?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/560?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/568?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/578?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/593?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/604?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/613?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/621?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/631?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/642?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/650?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/661?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/670?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/677?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/687?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/696?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/706?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/718?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/732?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/740?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/749?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/759?rss=1" />
  <rdf:li rdf:resource="http://www.jimmunol.org/cgi/content/short/183/1/770?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://www.jimmunol.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://www.jimmunol.org/icons/banner/title.gif">
<title>The Journal of Immunology</title>
<url>http://www.jimmunol.org/icons/banner/title.gif</url>
<link>http://www.jimmunol.org</link>
</image>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/1?rss=1">
<title><![CDATA[[IN THIS ISSUE] IN THIS ISSUE]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/1?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0990044</dc:identifier>
<dc:title><![CDATA[[IN THIS ISSUE] IN THIS ISSUE]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>2</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>1</prism:startingPage>
<prism:section>IN THIS ISSUE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/3?rss=1">
<title><![CDATA[[PILLARS OF IMMUNOLOGY] The Original Intrathymic Progenitor from Which T Cells Originate]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/3?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Zuniga-Pflucker, J. C.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0990043</dc:identifier>
<dc:title><![CDATA[[PILLARS OF IMMUNOLOGY] The Original Intrathymic Progenitor from Which T Cells Originate]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>4</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>3</prism:startingPage>
<prism:section>PILLARS OF IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/5?rss=1">
<title><![CDATA[[PILLARS OF IMMUNOLOGY] Pillars Article: Early T Lymphocytes. Differentiation In Vivo of Adult Intrathymic Precursor Cells. J. Exp. Med. 1985. 162: 802-822]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/5?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Fowlkes, B. J., Edison, L., Mathieson, B. J., Chused, T. M.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/</dc:identifier>
<dc:title><![CDATA[[PILLARS OF IMMUNOLOGY] Pillars Article: Early T Lymphocytes. Differentiation In Vivo of Adult Intrathymic Precursor Cells. J. Exp. Med. 1985. 162: 802-822]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>25</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>5</prism:startingPage>
<prism:section>PILLARS OF IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/27?rss=1">
<title><![CDATA[[CUTTING EDGE] Cutting Edge: Cardiac Myosin Activates Innate Immune Responses through TLRs]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/27?rss=1</link>
<description><![CDATA[
<p>Autoimmune attack on the heart is linked to host immune responses against cardiac myosin, the most abundant protein in the heart. Although adaptive immunity is required for disease, little is known about innate immune mechanisms. In this study we report that human cardiac myosin (HCM) acted as an endogenous ligand to directly stimulate human TLRs 2 and 8 and to activate human monocytes to release proinflammatory cytokines. In addition, pathogenic epitopes of human cardiac myosin, the S2 fragment peptides S2-16 and S2-28, stimulated TLRs directly and activated human monocytes. Our data suggest that cardiac myosin and its pathogenic T cell epitopes may link innate and adaptive immunity in a novel mechanism that could promote chronic inflammation in the myocardium.</p>
]]></description>
<dc:creator><![CDATA[Zhang, P., Cox, C. J., Alvarez, K. M., Cunningham, M. W.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0800861</dc:identifier>
<dc:title><![CDATA[[CUTTING EDGE] Cutting Edge: Cardiac Myosin Activates Innate Immune Responses through TLRs]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>31</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>27</prism:startingPage>
<prism:section>CUTTING EDGE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/32?rss=1">
<title><![CDATA[[CUTTING EDGE] Cutting Edge: B and T Lymphocyte Attenuator Signaling on NKT Cells Inhibits Cytokine Release and Tissue Injury in Early Immune Responses]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/32?rss=1</link>
<description><![CDATA[
<p>The role of coinhibition in an immune response is thought to be critical for the contraction of an adaptive immune response in its waning phases. We present evidence that B and T lymphocyte attenuator (BTLA) coinhibitory signaling is required to temper early inflammation. Using an in vivo Con A challenge model of acute hepatitis, we observed reduced survival and increased early serum cytokine secretion in BTLA<sup>&ndash;/&ndash;</sup> mice as compared with wild-type mice. In vitro, liver mononuclear cells from BTLA<sup>&ndash;/&ndash;</sup> mice are hyperresponsive to anti-CD3, Con A, and -galactosylceramide stimulation and secrete higher levels of TNF-, IFN-, IL-2, and IL-4. We found this was in part due to negative regulation of NKT cells by BTLA, as early cytokine inhibition from whole liver mononuclear cells or purified NKT cells depends upon BTLA signaling. Overall, our data demonstrate that coinhibition is active in early immune responses through BTLA regulation of NKT cells.</p>
]]></description>
<dc:creator><![CDATA[Miller, M. L., Sun, Y., Fu, Y.-X.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900690</dc:identifier>
<dc:title><![CDATA[[CUTTING EDGE] Cutting Edge: B and T Lymphocyte Attenuator Signaling on NKT Cells Inhibits Cytokine Release and Tissue Injury in Early Immune Responses]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>36</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>32</prism:startingPage>
<prism:section>CUTTING EDGE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/37?rss=1">
<title><![CDATA[[CUTTING EDGE] Cutting Edge: Rapid and Efficient In Vivo Cytotoxicity by Cytotoxic T Cells Is Independent of Granzymes A and B]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/37?rss=1</link>
<description><![CDATA[
<p>Cytotoxic T (Tc) cells lyse target cells via exocytosis of granules containing perforin (perf) and granzymes (gzm). In vitro, gzm delivery into the target cell cytosol results in apoptosis, and in the absence of gzm A and B the induction of apoptosis is severely impaired. However, using in vivo Tc cell killing assays, we find that virus-immune, gzm A <FONT FACE="arial,helvetica">x</FONT> B-deficient (gzmA<FONT FACE="arial,helvetica">x</FONT>B<sup>&ndash;/&ndash;</sup>) mice are competent to eliminate adoptively transferred target cells pulsed with an immunodominant Tc cell determinant as rapidly and completely as their wild-type counterparts. Specific target cell elimination occurred with similar kinetics in both spleen and lymph nodes. Thus, neither gzmA nor gzmB are required for rapid and efficient in vivo cytotoxicity by Tc cells.</p>
]]></description>
<dc:creator><![CDATA[Regner, M., Pavlinovic, L., Koskinen, A., Young, N., Trapani, J. A., Mullbacher, A.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900466</dc:identifier>
<dc:title><![CDATA[[CUTTING EDGE] Cutting Edge: Rapid and Efficient In Vivo Cytotoxicity by Cytotoxic T Cells Is Independent of Granzymes A and B]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>40</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>37</prism:startingPage>
<prism:section>CUTTING EDGE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/41?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] CD44high Memory CD8 T Cells Synergize with CpG DNA to Activate Dendritic Cell IL-12p70 Production]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/41?rss=1</link>
<description><![CDATA[
<p>Protective memory CD8 T cell responses are generally associated with the rapid and efficient acquisition of CTL function. However, the ability of memory CD8 T cells to modulate immune responses through interactions with dendritic cells (DCs) during the early states of secondary Ag exposure is poorly understood. In this study, we show that murine Ag-specific CD44<sup>high</sup> CD8 T cells, representing CD8 T cells of the memory phenotype, potently activate DCs to produce high levels of IL-12p70 in conjunction with stimulation of DCs with the TLR 9 ligand, unmethylated CpG DNA. IL-12p70 production was produced predominantly by CD8<sup>+</sup> DCs and plasmacytoid DCs, and mediated by CD8 T cell-derived cytokines IFN-, GM-CSF, TNF-, and surface CD40L. We also find that CD44<sup>high</sup> memory phenotype CD8 T cells were better DC IL-12p70 stimulators than CD44<sup>low</sup> naive phenotype CD8 T cells, and this was attributed to higher levels of IFN- and GM-CSF produced by CD44<sup>high</sup> memory phenotype CD8 T cells during their Ag specific interaction with DCs. Our study identifies CpG DNA as the most effective TLR ligand that cooperates with CD8 T cells for DC IL-12p70 production, and suggests that effectiveness of memory CD8 T cells could be attributed to their ability to rapidly and effectively induce protective Th1 immunity during early stages of pathogen reinfection.</p>
]]></description>
<dc:creator><![CDATA[Wong, K. L., Tang, L. F. M., Lew, F. C., Wong, H. S. K., Chua, Y. L., MacAry, P. A., Kemeny, D. M.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803473</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] CD44high Memory CD8 T Cells Synergize with CpG DNA to Activate Dendritic Cell IL-12p70 Production]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>50</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>41</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/51?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] IFN-{gamma} Promotes Generation of IL-10 Secreting CD4+ T Cells that Suppress Generation of CD8 Responses in an Antigen-Experienced Host]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/51?rss=1</link>
<description><![CDATA[
<p>Ags characterizing tumors or chronic viral infection are generally presented to the host immune system before specific immunotherapy is initiated, and consequent generation of regulatory CD4<sup>+</sup> T cells can inhibit induction of desired effector CD8 T cell responses. IL-10 produced in response to ongoing Ag exposure inhibits generation of CD8 T cells in an Ag-experienced host. We now show that this IL-10 is produced by Ag experienced CD4<sup>+</sup> glucocorticoid-induced tumor necrosis factor receptor<sup>+</sup> T cells that also secrete IFN- upon antigenic stimulation, that IL-10 secretion by these cells is enhanced through IFN- signaling, and, unexpectedly, that IFN- signaling is required for inhibition of generation of Ag-specific CD8 T cell responses in an Ag-experienced host. Systemic inhibition of both IL-10 and IFN- at the time of immunization may therefore facilitate induction of effective immunotherapeutic responses against tumor specific and viral Ags.</p>
]]></description>
<dc:creator><![CDATA[Liu, X. S., Leerberg, J., MacDonald, K., Leggatt, G. R., Frazer, I. H.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802047</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] IFN-{gamma} Promotes Generation of IL-10 Secreting CD4+ T Cells that Suppress Generation of CD8 Responses in an Antigen-Experienced Host]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>58</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>51</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/59?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Restricted Autoantigen Recognition Associated with Deletional and Adaptive Regulatory Mechanisms]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/59?rss=1</link>
<description><![CDATA[
<p>Autoimmune diabetes (T1D) is characterized by CD4<sup>+</sup> T cell reactivity to a variety of islet-associated Ags. At-risk individuals, genetically predisposed to T1D, often have similar T cell reactivity, but nevertheless fail to progress to clinically overt disease. To study the immune tolerance and regulatory environment permissive for such autoreactive T cells, we expressed TCR transgenes derived from two autoreactive human T cells, 4.13 and 164, in HLA-DR4 transgenic mice on a C57BL/6-derived "diabetes-resistant" background. Both TCR are responsive to an immunodominant epitope of glutamic acid decarboxylase 65<SUB>555&ndash;567</SUB>, which is identical in sequence between humans and mice, is restricted by HLA-DR4, and is a naturally processed self Ag associated with T1D. Although both TCR use the identical V and V&beta; genes, differing only in CDR3, we found stark differences in the mechanisms utilized in vivo in the maintenance of immune tolerance. A combination of thymic deletion (negative selection), TCR down-regulation, and peripheral activation-induced cell death dominated the phenotype of 164 T cells, which nevertheless still maintain their Ag responsiveness in the periphery. In contrast, 4.13 T cells are much less influenced by central and deletional tolerance mechanisms, and instead display a peripheral immune deviation including differentiation into IL-10-secreting Tr1 cells. These findings indicate a distinct set of regulatory alternatives for autoreactive T cells, even within a single highly restricted HLA-peptide-TCR recognition profile.</p>
]]></description>
<dc:creator><![CDATA[Gebe, J. A., Yue, B. B., Unrath, K. A., Falk, B. A., Nepom, G. T.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0804046</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Restricted Autoantigen Recognition Associated with Deletional and Adaptive Regulatory Mechanisms]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>65</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>59</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/66?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Aryl Hydrocarbon Receptor Activation Inhibits In Vitro Differentiation of Human Monocytes and Langerhans Dendritic Cells]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/66?rss=1</link>
<description><![CDATA[
<p>The transcription factor aryl hydrocarbon receptor (AhR) represents a promising therapeutic target in allergy and autoimmunity. AhR signaling induced by the newly described ligand VAF347 inhibits allergic lung inflammation as well as suppresses pancreatic islet allograft rejection. These effects are likely mediated via alterations in dendritic cell (DC) function. Moreover, VAF347 induces tolerogenic DCs. Langerhans cells (LCs) are immediate targets of exogenous AhR ligands at epithelial surfaces; how they respond to AhR ligands remained undefined. We studied AhR expression and function in human LCs and myelopoietic cell subsets using a lineage differentiation and gene transduction model of human CD34<sup>+</sup> hematopoietic progenitors. We found that AhR is highly regulated during myeloid subset differentiation. LCs expressed highest AhR levels followed by monocytes. Conversely, neutrophil granulocytes lacked AhR expression. AhR ligands including VAF347 arrested the differentiation of monocytes and LCs at an early precursor cell stage, whereas progenitor cell expansion or granulopoiesis remained unimpaired. AhR expression was coregulated with the transcription factor PU.1 during myeloid subset differentiation. VAF347 inhibited PU.1 induction during initial monocytic differentiation, and ectopic PU.1 restored monocyte and LC generation in the presence of this compound. AhR ligands failed to interfere with cytokine receptor signaling during LC differentiation and failed to impair LC activation/maturation. VAF347-mediated antiproliferative effect on precursors undergoing LC lineage differentiation occurred in a clinically applicable serum-free culture model and was not accompanied by apoptosis induction. In conclusion, AhR agonist signaling interferes with transcriptional processes leading to monocyte/DC lineage commitment of human myeloid progenitor cells.</p>
]]></description>
<dc:creator><![CDATA[Platzer, B., Richter, S., Kneidinger, D., Waltenberger, D., Woisetschlager, M., Strobl, H.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802997</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Aryl Hydrocarbon Receptor Activation Inhibits In Vitro Differentiation of Human Monocytes and Langerhans Dendritic Cells]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>74</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>66</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/75?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] T-bet-Deficient NOD Mice Are Protected from Diabetes Due to Defects in Both T Cell and Innate Immune System Function]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/75?rss=1</link>
<description><![CDATA[
<p>The transcription factor T-bet (<I>Tbx21</I>) is critical for Th1 polarization of CD4<sup>+</sup> T cells. Genetic deletion of <I>Tbx21</I> can cause either exacerbation or attenuation of different autoimmune diseases in animal models. In the nonobese diabetic (NOD) mouse, genetic deletion of the <I>Ifng</I> or the <I>Il12b</I> (IL-12p40) genes, which are both critical Th1 cytokines, does not reduce the incidence of autoimmune diabetes. These results suggest that autoimmune diabetes in the NOD may not be a Th1-driven disease. However, we report that <I>Tbx21</I> deficiency in the NOD mouse completely blocks insulitis and diabetes due to defects both in the initiation of the anti-islet immune response and in the function of CD4<sup>+</sup> effector T cells. We find defective priming of naive islet-reactive T cells by the innate immune system in <I>Tbx21</I><sup>&ndash;/&ndash;</sup> animals. By contrast to naive cells, activated islet-reactive BDC2.5 TCR-transgenic T cells do not require <I>Tbx21</I> in recipient animals for efficient adoptive transfer of diabetes. However, when these BDC2.5 TCR-transgenic effector cells lack <I>Tbx21</I>, they are less effective at entering the pancreas and promoting diabetes than <I>Tbx21</I><sup>+/+</sup> cells. <I>Tbx21</I><sup>&ndash;/&ndash;</sup> regulatory T cells function normally in vitro and diabetes can be restored in <I>Tbx21</I><sup>&ndash;/&ndash;</sup> mice by reducing regulatory T cell numbers. Thus, the absence of diabetes in the NOD.<I>Tbx21</I><sup>&ndash;/&ndash;</sup> is due to intrinsic defects in both T cells and cells of the innate immune system paired with the relative preservation of regulatory T cell function.</p>
]]></description>
<dc:creator><![CDATA[Esensten, J. H., Lee, M. R., Glimcher, L. H., Bluestone, J. A.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0804154</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] T-bet-Deficient NOD Mice Are Protected from Diabetes Due to Defects in Both T Cell and Innate Immune System Function]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>82</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>75</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/83?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Conservation of Structural and Functional Features in a Primordial CD80/86 Molecule from Rainbow Trout (Oncorhynchus mykiss), a Primitive Teleost Fish]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/83?rss=1</link>
<description><![CDATA[
<p>In mammals, interaction of CD28 with CD80 or CD86 molecules provides costimulatory signals for T cell activation that leads to increased IL-2 gene and protein expression by activated T cells. Thus far, CD80 and CD86 have been cloned and functionally characterized only in mammals and birds. To shed light into the evolution of CD80 and CD86, we have cloned and functionally characterized a rainbow trout (rt) molecule (rtCD80/86) that shows the highest degree of sequence conservation and phylogenetic relationship with CD80 and CD86 molecules. Moreover, its genomic organization was almost identical to that of human CD86. Rainbow trout possess one membrane-bound and two soluble CD80/86 transcripts, all of which are derived from the same rtCD80/86 gene. The membrane-bound form exhibited its highest degree of expression in lymphoid tissues, particularly on B cells. Incubation of trout leukocytes with LPS and bacteria leads to up-regulation of rtCD80/86 gene expression. Importantly, we show that trout and other teleost fish contain a single CD80/86 gene, thus suggesting that this gene may represent the ancestor from which CD80 and CD86 arose by gene duplication in more evolved species. To gain further insights into the function of rtCD80/86, we have identified and cloned trout IL-2 and have shown that recombinantly produced trout CD80/86 up-regulates the expression of IL-2 in trout blood leukocytes. Significantly, this finding indicates that the capacity to modulate IL-2 expression is a primordial function that has been conserved both in fish and mammalian CD80/CD86 molecules throughout 350 million years of evolution.</p>
]]></description>
<dc:creator><![CDATA[Zhang, Y.-A., Hikima, J.-i., Li, J., LaPatra, S. E., Luo, Y.-P., Sunyer, J. O.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900605</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Conservation of Structural and Functional Features in a Primordial CD80/86 Molecule from Rainbow Trout (Oncorhynchus mykiss), a Primitive Teleost Fish]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>96</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>83</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/97?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] TGF-{beta} Promotes Th17 Cell Development through Inhibition of SOCS3]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/97?rss=1</link>
<description><![CDATA[
<p>TGF-&beta;, together with IL-6 and IL-21, promotes Th17 cell development. IL-6 and IL-21 induce activation of STAT3, which is crucial for Th17 cell differentiation, as well as the expression of suppressor of cytokine signaling (SOCS)3, a major negative feedback regulator of STAT3-activating cytokines that negatively regulates Th17 cells. However, it is still largely unclear how TGF-&beta; regulates Th17 cell development and which TGF-&beta; signaling pathway is involved in Th17 cell development. In this report, we demonstrate that TGF-&beta; inhibits IL-6- and IL-21-induced SOCS3 expression, thus enhancing as well as prolonging STAT3 activation in naive CD4<sup>+</sup>CD25<sup>&ndash;</sup> T cells. TGF-&beta; inhibits IL-6-induced SOCS3 promoter activity in T cells. Also, SOCS3 small interfering RNA knockdown partially compensates for the action of TGF-&beta; on Th17 cell development. In mice with a dominant-negative form of TGF-&beta; receptor II and impaired TGF-&beta; signaling, IL-6-induced CD4<sup>+</sup> T cell expression of SOCS3 is higher whereas STAT3 activation is lower compared with wild-type B6 CD4<sup>+</sup> T cells. The addition of a TGF-&beta; receptor I kinase inhibitor that blocks Smad-dependent TGF-&beta; signaling greatly, but not completely, abrogates the effect of TGF-&beta; on Th17 cell differentiation. Our data indicate that inhibition of SOCS3 and, thus, enhancement of STAT3 activation is at least one of the mechanisms of TGF-&beta; promotion of Th17 cell development.</p>
]]></description>
<dc:creator><![CDATA[Qin, H., Wang, L., Feng, T., Elson, C. O., Niyongere, S. A., Lee, S. J., Reynolds, S. L., Weaver, C. T., Roarty, K., Serra, R., Benveniste, E. N., Cong, Y.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0801986</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] TGF-{beta} Promotes Th17 Cell Development through Inhibition of SOCS3]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>105</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>97</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/106?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] The Expression and Function of the NKRP1 Receptor Family in C57BL/6 Mice]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/106?rss=1</link>
<description><![CDATA[
<p>NKRP1 receptors were discovered more than 20 years ago, but due to a lack of appropriate reagents, our understanding of them has remained limited. Using a novel panel of mAbs that specifically recognize mouse NKRP1A, D, and F molecules, we report here that NKRP1D expression is limited to a subpopulation of NK cells, but in contrast to Ly49 receptors appears to be expressed in a normal codominant manner. NKRP1D<sup>&ndash;</sup> and NKRP1D<sup>+</sup> NK cells are functionally distinct, NKRP1D<sup>+</sup> cells showing reduced expression of various Ly49 receptors, elevated expression of CD94/NKG2 receptors, and higher IFN- secretion and cytotoxicity than NKRP1D<sup>&ndash;</sup> cells. Furthermore, NKRP1D<sup>+</sup> NK cells were unable to kill transfected cells expressing high levels of Clr-b molecules, but readily killed MHC class-I-deficient blast cells that express only low levels of Clr-b. NKRP1A and NKRP1F were expressed at low levels on all splenic and bone marrow NK cells, but mAb-induced cross-linking of NKRP1A and NKRP1F caused no significant enhancement or inhibition of NK cell cytotoxicity and no detectable production of IFN-. NKRP1A, D, and F expression could not be detected on NKT cells, all of which express NKRP1C, and although some activated T cells expressed NKRP1C and perhaps low levels of NKRP1A, no significant expression of NKRP1D or F could be detected. NKRP1 molecules expressed on NK cells or transfectants were down-regulated by cross-linking with mAbs or cell surface ligands, and using this phenomenon as a functional assay for NKRP1-ligand interaction revealed that NKRP1F can recognize CLR-x.</p>
]]></description>
<dc:creator><![CDATA[Aust, J. G., Gays, F., Mickiewicz, K. M., Buchanan, E., Brooks, C. G.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0804281</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] The Expression and Function of the NKRP1 Receptor Family in C57BL/6 Mice]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>116</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>106</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/117?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Modulating the Expression of IFN Regulatory Factor 8 Alters the Protumorigenic Behavior of CD11b+Gr-1+ Myeloid Cells]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/117?rss=1</link>
<description><![CDATA[
<p>CD11b<sup>+</sup>Gr-1<sup>+</sup>-expressing cells, termed myeloid-derived suppressor cells, can mediate immunosuppression and tumor progression. However, the intrinsic molecular events that drive their protumorigenic behavior remain to be elucidated. Although CD11b<sup>+</sup>Gr-1<sup>+</sup> cells exist at low frequencies in normal mice, it also remains unresolved whether they are biologically distinct from those of tumor-bearing hosts. These objectives were investigated using CD11b<sup>+</sup>Gr-1<sup>+</sup> cells from both implantable (4T1) and autochthonous (mouse mammary tumor virus-polyomavirus middle T Ag (MMTV-PyMT)) mouse models of mammary carcinoma. Limited variation was observed in the expression of markers associated with immunoregulation between CD11b<sup>+</sup>Gr-1<sup>+</sup> cells of both tumor models, as well as with their respective controls (Cnt). Despite limited differences in phenotype, tumor-induced CD11b<sup>+</sup>Gr-1<sup>+</sup> cells were found to produce a more immunosuppressive cytokine profile than that observed by Cnt CD11b<sup>+</sup>Gr-1<sup>+</sup> cells. Furthermore, when admixed with tumor cells, CD11b<sup>+</sup>Gr-1<sup>+</sup> cells from tumor-bearing mice significantly enhanced neoplastic growth compared with counterpart cells from Cnt mice. However, the protumorigenic behavior of these tumor-induced CD11b<sup>+</sup>Gr-1<sup>+</sup> cells was significantly diminished when the expression of IFN regulatory factor 8, a key myeloid-associated transcription factor, was enhanced. The loss of this protumorigenic effect occurred independently of the host immune system and correlated with a CD11b<sup>+</sup>Gr-1<sup>+</sup> cytokine/chemokine production pattern that resembled cells from nontumor-bearing Cnt mice. Overall, our data indicate that 1) tumor-induced CD11b<sup>+</sup>Gr-1<sup>+</sup> cells from both cancer models were phenotypically similar, but biologically distinct from their nontumor-bearing counterparts and 2) modulation of IFN regulatory factor 8 levels in tumor-induced CD11b<sup>+</sup>Gr-1<sup>+</sup> cells can significantly abrogate their protumorigenic behavior, which may have important implications for cancer therapy.</p>
]]></description>
<dc:creator><![CDATA[Stewart, T. J., Liewehr, D. J., Steinberg, S. M., Greeneltch, K. M., Abrams, S. I.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0804132</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Modulating the Expression of IFN Regulatory Factor 8 Alters the Protumorigenic Behavior of CD11b+Gr-1+ Myeloid Cells]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>128</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>117</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/129?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Increased Antigen Cross-Presentation but Impaired Cross-Priming after Activation of Peroxisome Proliferator-Activated Receptor {gamma} Is Mediated by Up-Regulation of B7H1]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/129?rss=1</link>
<description><![CDATA[
<p>Dendritic cells are able to take up exogenous Ags and present Ag-derived peptides on MHC class I molecules, a process termed cross-presentation. The mannose receptor (MR), an endocytic receptor expressed on a variety of APCs, has been demonstrated to target soluble Ags exclusively toward cross-presentation. In this study, we investigated the role of the murine nuclear receptor peroxisome proliferator-activated receptor  (PPAR), a ligand-activated transcription factor with immunomodulatory properties, in MR-mediated endocytosis and cross-presentation of the model Ag OVA. We could demonstrate both in vitro and in vivo that activation of PPAR resulted in increased MR expression, which in consequence led to enhanced MR-mediated endocytosis and elevated cross-presentation of soluble OVA. Concomitantly, activation of PPAR in dendritic cells induced up-regulation of the coinhibitory molecule B7H1, which, despite enhanced cross-presentation, caused an impaired activation of naive OVA-specific CD8<sup>+</sup> T cells and the induction of T cell tolerance. These data provide a mechanistic basis for the immunomodulatory action of PPAR which might open new possibilities in the development of therapeutic approaches aimed at the control of excessive immune responses, e.g., in T cell-mediated autoimmunity.</p>
]]></description>
<dc:creator><![CDATA[Klotz, L., Hucke, S., Thimm, D., Classen, S., Gaarz, A., Schultze, J., Edenhofer, F., Kurts, C., Klockgether, T., Limmer, A., Knolle, P., Burgdorf, S.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0804260</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Increased Antigen Cross-Presentation but Impaired Cross-Priming after Activation of Peroxisome Proliferator-Activated Receptor {gamma} Is Mediated by Up-Regulation of B7H1]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>136</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>129</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/137?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/137?rss=1</link>
<description><![CDATA[
<p>Antineoplastic chemotherapeutic agents may indirectly activate dendritic cells (DCs) by inducing the release of "danger" signals from dying tumor cells. Whereas the direct cytotoxic or inhibitory effect of conventional chemotherapy on DCs has been reported, modulation of DC function by chemotherapeutic agents in low noncytotoxic concentrations has not yet been investigated. We have tested the effects of different classes of antineoplastic chemotherapeutic agents used in low noncytotoxic concentrations on the Ag-presenting function of DCs. We revealed that paclitaxel, doxorubicin, mitomycin C, and methotrexate up-regulated the ability of DCs to present Ags to Ag-specific T cells. Stimulation of DC function was associated with the up-regulation of expression of Ag-processing machinery components and costimulatory molecules on DCs, as well as increased IL-12p70 expression. However, the ability of DCs treated with paclitaxel, methotrexate, doxorubicin, and vinblastine to increase Ag presentation to Ag-specific T cells was abolished in DCs generated from IL-12 knockout mice, indicating that up-regulation of Ag presentation by DCs is IL-12-dependent and mediated by the autocrine or paracrine mechanisms. At the same time, IL-12 knockout and wild-type DCs demonstrated similar capacity to up-regulate OVA presentation after their pretreatment with low concentrations of mitomycin C and vincristine, suggesting that these agents do not utilize IL-12-mediated pathways in DCs for stimulating Ag presentation. These findings reveal a new mechanism of immunopotentiating activity of chemotherapeutic agents&mdash;a direct immunostimulatory effect on DCs (chemomodulation)&mdash;and thus provide a strong rationale for further assessment of low-dose chemotherapy given with DC vaccines for cancer treatment.</p>
]]></description>
<dc:creator><![CDATA[Shurin, G. V., Tourkova, I. L., Kaneno, R., Shurin, M. R.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900734</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>144</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>137</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/145?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Tryptophan Deprivation Induces Inhibitory Receptors ILT3 and ILT4 on Dendritic Cells Favoring the Induction of Human CD4+CD25+ Foxp3+ T Regulatory Cells]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/145?rss=1</link>
<description><![CDATA[
<p>Tryptophan catabolism through IDO activity can cause nonresponsiveness and tolerance acting on T cells. Given the crucial importance of dendritic cells (DCs) in the initiation of a T cell response, surprisingly little is known about the impact of IDO activity and tryptophan deprivation on DCs themselves. In the present study, we show that human DCs differentiated under low-tryptophan conditions acquire strong tolerogenic capacity. This effect is associated with a markedly decreased Ag uptake as well as the down-regulation of costimulatory molecules (CD40, CD80). In contrast, the inhibitory receptors ILT3 and ILT4 are significantly increased. Functionally, tryptophan-deprived DCs show a reduced capacity to stimulate T cells, which can be restored by blockade of ILT3. Moreover, ILT3<sup>high</sup>ILT4<sup>high</sup> DCs lead to the induction of CD4<sup>+</sup>CD25<sup>+</sup> Foxp3<sup>+</sup> T regulatory cells with suppressive activity from CD4<sup>+</sup>CD25<sup>&ndash;</sup> T cells. The generation of ILT3<sup>high</sup>ILT4<sup>high</sup> DCs with tolerogenic properties by tryptophan deprivation is linked to a stress response pathway mediated by the GCN2 kinase. These results demonstrate that tryptophan degradation establishes a regulatory microenvironment for DCs, enabling these cells to induce T regulatory cells. The impact of IDO thus extends beyond local immune suppression to a systemic control of the immune response.</p>
]]></description>
<dc:creator><![CDATA[Brenk, M., Scheler, M., Koch, S., Neumann, J., Takikawa, O., Hacker, G., Bieber, T., von Bubnoff, D.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803277</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Tryptophan Deprivation Induces Inhibitory Receptors ILT3 and ILT4 on Dendritic Cells Favoring the Induction of Human CD4+CD25+ Foxp3+ T Regulatory Cells]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>154</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>145</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/155?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] STAT6 Activation Confers upon T Helper Cells Resistance to Suppression by Regulatory T Cells]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/155?rss=1</link>
<description><![CDATA[
<p>Recent studies have highlighted characteristics of T regulatory cells (Tregs) that underlie their suppressive function. However, mechanisms that override their suppressive function in the context of an adaptive immune response are not well understood. In the lungs of mice undergoing allergic inflammation, appreciable numbers of Tregs were identified that possessed suppressive function when assayed ex vivo. We investigated whether the Th2-promoting cytokine IL-4 played a permissive role that superseded Treg function, thereby allowing the development of allergic inflammation. IL-4 signaling via the IL-4R-STAT6 axis was required to maintain Foxp3 expression in Tregs and promote their proliferation. However, the results of both in vivo experiments involving adoptive transfer of Tregs into Ag-sensitized vs naive animals and in vitro suppression assays performed with or without exogenous IL-4 showed the ability of IL-4 to compromise Treg-mediated suppression. Use of retrovirally expressed, constitutively active STAT6 revealed that the underlying mechanism was not IL-4-mediated dysfunction of Tregs but involved the resistance of Th cells to Treg-mediated suppression that would permit the development of an adaptive immune response. Our data suggest that infectious tolerance, mediated by membrane-bound TGF-&beta; expressed by Tregs, is compromised by the competing effects of IL4-induced signaling in naive CD4<sup>+</sup> Th cells.</p>
]]></description>
<dc:creator><![CDATA[Pillemer, B. B. L., Qi, Z., Melgert, B., Oriss, T. B., Ray, P., Ray, A.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803733</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] STAT6 Activation Confers upon T Helper Cells Resistance to Suppression by Regulatory T Cells]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>163</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>155</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/164?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] The Effects of Cytokines on Suppression of Lymphocyte Proliferation by Dexamethasone]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/164?rss=1</link>
<description><![CDATA[
<p>Treatment failure occurs in up to 30% of patients treated with steroids for inflammatory diseases. The aim of this study was to explore the potential role of 21 cytokines in steroid-resistant inflammatory disease and to develop methods to restore steroid sensitivity through cytokine manipulation. The dexamethasone inhibition of lymphocyte proliferation assay correlates with the outcome of steroid therapy in ulcerative colitis (UC) and other inflammatory diseases. Using this assay, PBMC production of 21 cytokines, assayed by cytokine bead array, was correlated with percentage of suppression of proliferation by 10<sup>&ndash;6</sup> M dexamethasone (Imax) in 26 healthy volunteers. Effects of the addition of exogenous cytokines to induce steroid resistance in PBMCs from healthy volunteers and cytokine blockade to improve steroid sensitivity in PBMCs from patients with steroid-resistant UC were then explored. Production of IL-1, IL-10, IL-17, IFN-, G-CSF, GM-CSF, TNF-, and IFN-inducible protein 10 (IP-10) correlated significantly with in vitro steroid sensitivity; however, only IL-2 and TNF- reduced steroid sensitivity when added exogenously. Addition of IL-10 enhanced steroid suppression. Immunoneutralization or receptor blockade of IL-2, but not TNF-, IFN-, IL-4, IL-17, or IP-10 increased steroid sensitivity in cells from steroid-resistant UC patients. Neutralization of IL-10 reduced steroid sensitivity. Of the large panel of cytokines studied, IL-2 appears to have the greatest antagonistic effect on the antiproliferative effect of steroids. These data suggest that IL-2 inhibition in vivo may improve the response to steroids in steroid-resistant individuals.</p>
]]></description>
<dc:creator><![CDATA[Creed, T. J., Lee, R. W., Newcomb, P. V., di Mambro, A. J., Raju, M., Dayan, C. M.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0801998</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] The Effects of Cytokines on Suppression of Lymphocyte Proliferation by Dexamethasone]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>171</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>164</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/172?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Role of CD44 in the Differentiation of Th1 and Th2 Cells: CD44-Deficiency Enhances the Development of Th2 Effectors in Response to Sheep RBC and Chicken Ovalbumin]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/172?rss=1</link>
<description><![CDATA[
<p>CD4 T cells can be primarily polarized to differentiate into Th1 or Th2 cells. CD44 is a marker of T cell activation and a property of long-lived memory cells and implicated in cell migration, activation, and differentiation. To date, whether CD44 has a role in regulating Th1-Th2 differentiation has not been determined. In this study, we compared Th1 and Th2 responses in wild-type and CD44-deficient mice in response to sheep RBC and chicken OVA, as well as examined Th1-Th2 differentiation in vivo and in vitro from CD44-sufficient and CD44-deficient naive CD4 T cells. We observed that deficiency of CD44 tended to inhibit Th1 while promoting Th2 differentiation. Furthermore, chimeric studies suggested that CD44 expression by CD4 T cells was essential for such Th2 bias. The regulation by CD44 occurred at the transcription level leading to up-regulated GATA3 and down-regulated T-bet expression in activated CD4 T cells. We also noted that CD44-deficiency could modify the state of dendritic cell subsets to induce a Th2-biased development. Results presented in this study demonstrate for the first time that CD44 participates in the regulation of Th1-Th2 differentiation.</p>
]]></description>
<dc:creator><![CDATA[Guan, H., Nagarkatti, P. S., Nagarkatti, M.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802325</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Role of CD44 in the Differentiation of Th1 and Th2 Cells: CD44-Deficiency Enhances the Development of Th2 Effectors in Response to Sheep RBC and Chicken Ovalbumin]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>180</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>172</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/181?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Vaccine-Induced CD8+ T Cell-Dependent Suppression of Airway Hyperresponsiveness and Inflammation]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/181?rss=1</link>
<description><![CDATA[
<p>Suppressing the abnormalities associated with asthma has been difficult to accomplish using immunotherapy or vaccination once the disease is established. The effector cells necessary for effective immunization/vaccination and immunotherapy of asthma are also not well understood. Therefore, we vaccinated allergen (OVA)-sensitized mice to determine whether therapeutic immunization could suppress airway hyperresponsiveness (AHR) and inflammation and to identify key immune effector cells and cytokines. Mice were immunized with a vaccine comprised of Ag and cationic liposome-DNA complexes (CLDC), a vaccine which has previously been shown to elicit strong CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses and activation of Th1 immunity. We showed that immunization with the OVA-CLDC vaccine significantly suppressed AHR, eosinophilia, goblet cell metaplasia, and Th2 cytokine production. In contrast, immunization with CLDC alone suppressed eosinophilia and Th2 cytokine production, but failed to suppress AHR and goblet cell changes. Using adoptive transfer experiments, we found that suppression of AHR was mediated by Ag-specific CD8<sup>+</sup> T cells and was dependent on IFN- production by the transferred T cells. Thus, we conclude that generation of strong, allergen-specific CD8<sup>+</sup> T cell responses by immunization may be capable of suppressing AHR and allergic airway inflammation, even in previously sensitized and challenged mice.</p>
]]></description>
<dc:creator><![CDATA[Takeda, K., Dow, S. W., Miyahara, N., Kodama, T., Koya, T., Taube, C., Joetham, A., Park, J.-W., Dakhama, A., Kedl, R. M., Gelfand, E. W.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803967</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Vaccine-Induced CD8+ T Cell-Dependent Suppression of Airway Hyperresponsiveness and Inflammation]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>190</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>181</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/191?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] A Microbial Polysaccharide Reduces the Severity of Rheumatoid Arthritis by Influencing Th17 Differentiation and Proinflammatory Cytokines Production]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/191?rss=1</link>
<description><![CDATA[
<p>Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease characterized by chronic joint inflammation with subsequent cartilage and bone destruction. RA is emerging as a model of IL-17-driven autoimmune inflammatory disease. IL-17 is a marker for Th17 cells, with its master regulator being the retinoic acid receptor-related orphan receptor (RORt) regulated by STAT3 signaling. Glucuronoxylomannan (GXM), a polysaccharide representing the main component of the capsular material of the opportunistic yeast <I>Cryptococcus neoformans</I>, exhibits potent immunosuppressive properties both in vitro and in vivo. The present study investigates the effects of GXM treatment on the progression of collagen-induced arthritis. GXM suppressed clinical signs of collagen-induced arthritis and blocked joint erosion progression. This effect was mediated by down-regulation of key cytokines involved in the pathogenesis of RA such as TNF- and IL-1&beta;, and up-regulation of the inhibitory cytokine IL-10. Moreover, a reduction of IL-6 and TGF-&beta;, which inhibit Th17 differentiation with consequent decreased IL-17 production at the local and systemic level, was observed. The effect of GXM on Th17 differentiation mirrored the reduction in STAT3 activation and inhibition of RORt synthesis. Consequently, this work highlights the beneficial properties of an efficacious compound that could eventually be destined to the clinic.</p>
]]></description>
<dc:creator><![CDATA[Monari, C., Bevilacqua, S., Piccioni, M., Pericolini, E., Perito, S., Calvitti, M., Bistoni, F., Kozel, T. R., Vecchiarelli, A.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0804144</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] A Microbial Polysaccharide Reduces the Severity of Rheumatoid Arthritis by Influencing Th17 Differentiation and Proinflammatory Cytokines Production]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>200</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>191</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/201?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Cytokine-Dependent Modification of IL-12p70 and IL-23 Balance in Dendritic Cells by Ligand Activation of V{alpha}24 Invariant NKT Cells]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/201?rss=1</link>
<description><![CDATA[
<p>CD1d-restricted invariant NKT (iNKT) cells play crucial roles in various types of immune responses, including autoimmune diseases, infectious diseases and tumor surveillance. The mechanisms underlying their adjuvant functions are well understood. Nevertheless, although IL-4 and IL-10 production characterize iNKT cells able to prevent or ameliorate some autoimmune diseases and inflammatory conditions, the precise mechanisms by which iNKT cells exert immune regulatory function remain elusive. This study demonstrates that the activation of human iNKT cells by their specific ligand -galactosylceramide enhances IL-12p70 while inhibiting the IL-23 production by monocyte-derived dendritic cells, and in turn down-regulating the IL-17 production by memory CD4<sup>+</sup> Th cells. The ability of the iNKT cells to regulate the differential production of IL-12p70/IL-23 is mainly mediated by a remarkable hallmark of their function to produce both Th1 and Th2 cytokines. In particular, the down-regulation of IL-23 is markedly associated with a production of IL-4 and IL-10 from iNKT cells. Moreover, Th2 cytokines, such as IL-4 and IL-13 play a crucial role in defining the biased production of IL-12p70/IL-23 by enhancement of IL-12p70 in synergy with IFN-, whereas inhibition of the IFN--promoted IL-23 production. Collectively, the results suggest that iNKT cells modify the IL-12p70/IL-23 balance to enhance the IL-12p70-induced cell-mediated immunity and suppress the IL-23-dependent inflammatory pathologies. These results may account for the long-appreciated contrasting beneficial and adverse consequence of ligand activation of iNKT cells.</p>
]]></description>
<dc:creator><![CDATA[Uemura, Y., Liu, T.-Y., Narita, Y., Suzuki, M., Nakatsuka, R., Araki, T., Matsumoto, M., Iwai, L. K., Hirosawa, N., Matsuoka, Y., Murakami, M., Kimura, T., Hase, M., Kohno, H., Sasaki, Y., Ichihara, Y., Ishihara, O., Kikuchi, H., Sakamoto, Y., Jiao, S.-C., Senju, S., Sonoda, Y.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900873</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Cytokine-Dependent Modification of IL-12p70 and IL-23 Balance in Dendritic Cells by Ligand Activation of V{alpha}24 Invariant NKT Cells]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>208</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>201</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/209?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] IFN-{gamma} Attenuates Antigen-Induced Overall Immune Response in the Airway As a Th1-Type Immune Regulatory Cytokine]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/209?rss=1</link>
<description><![CDATA[
<p>Allergic inflammation in the airway is generally considered a Th2-type immune response. However, recent studies demonstrated that Th1- and Th17-type immune responses also play important roles in this process. IFN- is a Th1-type cytokine that generally counteracts the Th2 response. Although previous studies suggest that exogenous IFN- suppresses allergic airway inflammation, the mechanism of suppression has not been fully clarified. In this study, we elucidated whether IFN- suppresses Ag-induced immune responses including the production of Th1- and Th17-type cytokines in the lung, and examined its mechanism of action. BALB/c mice were sensitized and challenged with OVA-Ag to induce airway inflammation. An IFN--producing plasmid vector was delivered before systemic Ag sensitization. IFN- suppressed indicators of Th2-type immune responses such as airway eosinophilia, IL-5 and IL-13 production in the lung, and bronchial mucus production. Moreover, IFN- also suppressed the production of IL-17 and IFN- itself. The suppression was not mediated by inducing regulatory T cells or by inducing apoptosis in immunocytes. Instead, IFN- suppressed the Ag-presenting capacity and cytokine production of splenic dendritic cells and thus subsequently suppressed OVA-induced activation of CD4<sup>+</sup> T cells. Furthermore, IFN- also attenuated allergic airway inflammation when delivered during the OVA challenge. Various functions of lung CD11c<sup>+</sup> APCs and their migration to regional lymph nodes were also suppressed. These results suggest that the Th1 cytokine IFN- has broad immune regulatory potential through suppressing APC functions. They also suggest that delivery of IFN- could be an effective strategy for regulating Ag-induced immune responses in the lung.</p>
]]></description>
<dc:creator><![CDATA[Nakagome, K., Okunishi, K., Imamura, M., Harada, H., Matsumoto, T., Tanaka, R., Miyazaki, J.-i., Yamamoto, K., Dohi, M.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802712</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] IFN-{gamma} Attenuates Antigen-Induced Overall Immune Response in the Airway As a Th1-Type Immune Regulatory Cytokine]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>220</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>209</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/221?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Sphingosine Kinase1 Is Pivotal for Fc{epsilon}RI-Mediated Mast Cell Signaling and Functional Responses In Vitro and In Vivo]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/221?rss=1</link>
<description><![CDATA[
<p>Mast cell degranulation is pivotal to allergic diseases; investigating novel pathways triggering mast cell degranulation would undoubtedly have important therapeutic potential. FcRI-mediated degranulation has contradictorily been shown to require SphK1 or SphK2, depending on the reports. We investigated the in vitro and in vivo specific role(s) of SphK1 and SphK2 in FcRI-mediated responses, using specific small interfering RNA-gene silencing. The small interfering RNA-knockdown of SphK1 in mast cells inhibited several signaling mechanisms and effector functions, triggered by FcRI stimulation including: Ca<sup>2+</sup> signals, NFB activation, degranulation, cytokine/chemokine, and eicosanoid production, whereas silencing SphK2 had no effect at all. Moreover, silencing <I>SPHK1</I> in vivo, in different strains of mice, strongly inhibited mast cell-mediated anaphylaxis, including inhibition of vascular permeability, tissue mast cell degranulation, changes in temperature, and serum histamine and cytokine levels, whereas silencing <I>SPHK2</I> had no effect and the mice developed anaphylaxis. Our data differ from a recent report using <I>SPHK1</I><sup>&ndash;/&ndash;</sup> and <I>SPHK2</I><sup>&ndash;/&ndash;</sup> mice, which showed that SphK2 was required for FcRI-mediated mast cell responses. We performed experiments in mast cells derived from <I>SPHK1</I><sup>&ndash;/&ndash;</sup> and <I>SPHK2</I><sup>&ndash;/&ndash;</sup> mice and show that the calcium response and degranulation, triggered by FcRI-cross-linking, is not different from that triggered in wild-type cells. Moreover, IgE-mediated anaphylaxis in the knockout mice showed similar levels in temperature changes and serum histamine to that from wild-type mice, indicating that there was no protection from anaphylaxis for either knockout mice. Thus, our data strongly suggest a previously unrecognized compensatory mechanism in the knockout mice, and establishes a role for SphK1 in IgE-mediated mast cell responses.</p>
]]></description>
<dc:creator><![CDATA[Pushparaj, P. N., Manikandan, J., Tay, H. K., H'ng, S. C., Kumar, S. D., Pfeilschifter, J., Huwiler, A., Melendez, A. J.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803430</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Sphingosine Kinase1 Is Pivotal for Fc{epsilon}RI-Mediated Mast Cell Signaling and Functional Responses In Vitro and In Vivo]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>227</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>221</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/228?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] SHIP1 Is a Repressor of Mast Cell Hyperplasia, Cytokine Production, and Allergic Inflammation In Vivo]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/228?rss=1</link>
<description><![CDATA[
<p>SHIP1 inhibits immune receptor signaling through hydrolysis of the PI3K product phosphatidylinositol 3,4,5-trisphosphate, forming phosphatidylinositol 3,4-bisphosphate. In mast cells, SHIP1 represses FcRI- and cytokine-mediated activation in vitro, but little is known regarding the function of SHIP1 in mast cells in vivo or the susceptibility of <I>Ship1</I><sup>&ndash;/&ndash;</sup> mice to mast cell-associated diseases. In this study, we found that <I>Ship1</I><sup>&ndash;/&ndash;</sup> mice have systemic mast cell hyperplasia, increased serum levels of IL-6, TNF, and IL-5, and heightened anaphylactic response. Further, by reconstituting mast cell-deficient mice with <I>Ship1</I><sup>+/+</sup> or <I>Ship1</I><sup>&ndash;/&ndash;</sup> mast cells, we found that the above defects were due to loss of SHIP1 in mast cells. Additionally, we found that mice reconstituted with <I>Ship1</I><sup>&ndash;/&ndash;</sup> mast cells suffered worse allergic asthma pathology than those reconstituted with <I>Ship1</I><sup>+/+</sup> mast cells. In summary, our data show that SHIP1 represses allergic inflammation and mast cell hyperplasia in vivo and exerts these effects specifically in mast cells.</p>
]]></description>
<dc:creator><![CDATA[Haddon, D. J., Antignano, F., Hughes, M. R., Blanchet, M.-R., Zbytnuik, L., Krystal, G., McNagny, K. M.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900427</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] SHIP1 Is a Repressor of Mast Cell Hyperplasia, Cytokine Production, and Allergic Inflammation In Vivo]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>236</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>228</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/237?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Type V Collagen-Induced Oral Tolerance Plus Low-Dose Cyclosporine Prevents Rejection of MHC Class I and II Incompatible Lung Allografts]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/237?rss=1</link>
<description><![CDATA[
<p>Autoimmunity to type V collagen (col(V)) is a major risk factor for lung allograft rejection. Although col(V)-induced oral tolerance abrogates rejection of minor histoincompatible lung transplants, its ability to prevent rejection of fully MHC incompatible lung allografts is unknown. Rat lung allografts fully incompatible at MHC class I and II loci (Brown Norway (RT1<sup>n</sup>)) were transplanted into untreated Wistar Kyoto rat recipients (WKY, RT1<sup>l</sup>), or WKY rats were fed col(V) pretransplantation. To determine whether col(V) enhanced cyclosporine (CsA)-mediated immune suppression, WKY rats were treated with low-dose CsA (5 mg/kg), posttransplant, or oral col(V) plus CsA. The data showed that in contrast to col(V) or CsA, col(V) plus low-dose CsA significantly prevented rejection pathology, down-regulated alloantigen-induced production of IFN- and IL-17A, and suppressed chemotaxis for lung macrophages in allograft bronchoalveolar lavage fluid that was associated with lower local levels of MCP-1 (CCL2). Col(V) plus CsA was associated with alloantigen-induced expression of IL-10 in mediastinal lymph node or splenic T cells, intragraft expression of IL-10 and Foxp3 in perivascular and peribronchiolar mononuclear cells, and constitutive production of IL-10 from allograft alveolar macrophages. These data demonstrate that col(V) enhances low-dose CsA-mediated immune suppression, and suggest a role for oral col(V) in immune modulation in lung transplantation.</p>
]]></description>
<dc:creator><![CDATA[Yamada, Y., Sekine, Y., Yoshida, S., Yasufuku, K., Petrache, I., Benson, H. L., Brand, D. D., Yoshino, I., Wilkes, D. S.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0804028</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Type V Collagen-Induced Oral Tolerance Plus Low-Dose Cyclosporine Prevents Rejection of MHC Class I and II Incompatible Lung Allografts]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>245</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>237</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/246?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Regulatory Properties of Copolymer I in Th17 Differentiation by Altering STAT3 Phosphorylation]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/246?rss=1</link>
<description><![CDATA[
<p>Th17 and Th1 play an important role in multiple sclerosis for which copolymer I (COP-I) is a treatment option. We described here that the treatment effect of COP-I correlated with its unique regulatory properties on differentiation and survival of Th17 in experimental autoimmune encephalomyelitis mice, which was mediated through down-regulation of STAT3 phosphorylation. The effect of COP-I on Th17 differentiation required CD14<sup>+</sup> monocytes through IL-6 signaling as a key mediator to regulate STAT3 phosphorylation and subsequent RORt expression in Th17 cells. The observed effect was markedly dampened when monocytes were genetically deficient for IL-6. Similar regulatory properties of COP-I were demonstrated in human Th17 differentiation. The study revealed the differential regulatory roles and the novel mechanism of action of COP-I chiefly responsible for its treatment efficacy in experimental autoimmune encephalomyelitis and multiple sclerosis.</p>
]]></description>
<dc:creator><![CDATA[Chen, C., Liu, X., Wan, B., Zhang, J. Z.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900193</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Regulatory Properties of Copolymer I in Th17 Differentiation by Altering STAT3 Phosphorylation]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>253</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>246</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/254?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Production of Both IL-27 and IFN-{gamma} after the Treatment with a Ligand for Invariant NK T Cells Is Responsible for the Suppression of Th2 Response and Allergic Inflammation in a Mouse Experimental Asthma Model]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/254?rss=1</link>
<description><![CDATA[
<p>Using an allergen-induced airway inflammation model, we show that an injection of -galactosylceramide (-GalCer), a ligand for invariant NK T (iNKT) cells, induced IL-27 and that this process is essential for the attenuation of the Th2 response. After the systemic administration of -GalCer into the mice primed with OVA in alum, Th2 cytokine production of OVA-primed CD4<sup>+</sup> T cells in their lymph nodes, IgG1 and IgE Ab formation, and infiltration of eosinophils in bronchoalveolar lavage after the OVA challenge were suppressed. Systemic administration of rIFN- into OVA-primed mice could not reproduce these effects of -GalCer. IL-27p28 was detected both in the culture supernatant of -GalCer-stimulated spleen cells and in the serum of the -GalCer-treated mice, but not in the iNKT cell-deficient mice. Splenic iNKT cells produced IL-27p28 in the culture supernatant upon stimulation with PMA plus ionomycin, although the transcript of <I>IL-27p28</I> in the iNKT cells was constitutively expressed regardless of the stimulation. By contrast, the transcript of <I>IL-27EBI3</I> was induced in the iNKT cells upon stimulation with PMA plus ionomycin in vitro and with -GalCer treatment in vivo, suggesting that IL-27 (p28/EBI3) could be produced by iNKT cells in an activation-dependent manner. Although repeated injections of rIL-27 did not substitute for the effects of a single injection of -GalCer, administration of rIL-27 along with rIFN- reproduced in vivo effects of the -GalCer injection. These data indicate that production of both IL-27 and IFN- by the -GalCer treatment is responsible for suppression of the Th2 response and allergic inflammation.</p>
]]></description>
<dc:creator><![CDATA[Fujita, H., Teng, A., Nozawa, R., Takamoto-Matsui, Y., Katagiri-Matsumura, H., Ikezawa, Z., Ishii, Y.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0800520</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Production of Both IL-27 and IFN-{gamma} after the Treatment with a Ligand for Invariant NK T Cells Is Responsible for the Suppression of Th2 Response and Allergic Inflammation in a Mouse Experimental Asthma Model]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>260</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>254</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/261?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] MEK/ERK-Mediated Phosphorylation of Bim Is Required to Ensure Survival of T and B Lymphocytes during Mitogenic Stimulation]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/261?rss=1</link>
<description><![CDATA[
<p>Survival and death of lymphocytes are regulated by the balance between pro- and antiapoptotic members of the Bcl-2 family; this is coordinated with the control of cell cycling and differentiation. Bim, a proapoptotic BH3-only member of the Bcl-2 family, can be regulated by MEK/ERK-mediated phosphorylation, which affects its binding to pro&ndash;survival Bcl-2 family members and its turnover. We investigated Bim modifications in mouse B and T lymphoid cells after exposure to apoptotic stimuli and during mitogenic activation. Treatment with ionomycin or cytokine withdrawal caused an elevation in Bim<SUB>EL</SUB>, the most abundant Bim isoform. In contrast, in mitogenically stimulated T and B cells, Bim<SUB>EL</SUB> was rapidly phosphorylated, and its levels declined. Pharmacological inhibitors of MEK/ERK signaling prevented both of these changes in Bim, reduced proliferation, and triggered apoptosis of mitogen-stimulated T and B cells. Loss of Bim prevented this cell killing but did not restore cell cycling. These results show that during mitogenic stimulation of T and B lymphocytes MEK/ERK signaling is critical for two distinct processes, cell survival, mediated (at least in part) through phosphorylation and consequent inhibition of Bim, and cell cycling, which proceeds independently of Bim inactivation.</p>
]]></description>
<dc:creator><![CDATA[O'Reilly, L. A., Kruse, E. A., Puthalakath, H., Kelly, P. N., Kaufmann, T., Huang, D. C. S., Strasser, A.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803853</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] MEK/ERK-Mediated Phosphorylation of Bim Is Required to Ensure Survival of T and B Lymphocytes during Mitogenic Stimulation]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>269</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>261</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/270?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Blocking CD27-CD70 Costimulatory Pathway Suppresses Experimental Colitis]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/270?rss=1</link>
<description><![CDATA[
<p>The pathogenesis of human inflammatory bowel disease (IBD) and most experimental models of IBD is dependent on the activation and expansion of CD4<sup>+</sup> T cells via interaction with mucosal APCs. The costimulatory receptor CD70 is transiently expressed on the surface of conventional dendritic cells, but is constitutively expressed by a unique APC population in the intestinal lamina propria. We used two experimental IBD models to evaluate whether interfering the interaction between CD70 and its T cell ligand CD27 would affect the development of colitis. Adoptive transfer of naive CD27-deficient CD45RB<sup>high</sup> CD4<sup>+</sup> T cells into Rag-1<sup>&ndash;/&ndash;</sup> mice resulted in significantly less disease than when wild-type CD45RB<sup>high</sup>CD4<sup>+</sup> T cells were used. Moreover, a monoclonal anti-CD70 Ab prevented the disease caused by the transfer of wild-type CD45RB<sup>high</sup> CD4<sup>+</sup> T cells into Rag-1<sup>&ndash;/&ndash;</sup> mice and the same Ab also ameliorated an established disease. The colitis associated proinflammatory cytokines IL-6, TNF- and IFN- were significantly reduced after anti-CD70 Ab treatment, suggesting an overall reduction in inflammation due to blockade of pathogenic T cell expansion. Anti-CD70 Ab treatment also suppressed trinitrobenzene sulfonic acid-induced colitis in SJL/J mice. Because anti-CD70 Ab treatment suppressed multiple proinflammatory cytokines, this may be a more potent therapeutic approach for IBD than blockade of individual cytokines.</p>
]]></description>
<dc:creator><![CDATA[Manocha, M., Svend, R., Laouar, A., Liao, G., Bhan, A., Borst, J., Terhorst, C., Manjunath, N.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802424</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Blocking CD27-CD70 Costimulatory Pathway Suppresses Experimental Colitis]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>276</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>270</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/277?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Gap Junctions at the Dendritic Cell-T Cell Interface Are Key Elements for Antigen-Dependent T Cell Activation]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/277?rss=1</link>
<description><![CDATA[
<p>The acquired immune response begins with Ag presentation by dendritic cells (DCs) to naive T cells in a heterocellular cell-cell contact-dependent process. Although both DCs and T cells are known to express connexin43, a gap junction protein subunit, the role of connexin43 on the initiation of T cell responses remains to be elucidated. In the present work, we report the formation of gap junctions between DCs and T cells and their role on T cell activation during Ag presentation by DCs. In cocultures of DCs and T cells, Lucifer yellow microinjected into DCs is transferred to adjacent transgenic CD4<sup>+</sup> T cells, only if the specific antigenic peptide was present at least during the first 24 h of cocultures. This dye transfer was sensitive to gap junction blockers, such as oleamide, and small peptides containing the extracellular loop sequences of conexin. Furthermore, in this system, gap junction blockers drastically reduced T cell activation as reflected by lower proliferation, CD69 expression, and IL-2 secretion. This lower T cell activation produced by gap junction blockers was not due to a lower expression of CD80, CD86, CD40, and MHC-II on DCs. Furthermore, gap junction blocker did not affect polyclonal activation of T cell induced with anti-CD3 plus anti-CD28 Abs in the absence of DCs. These results strongly suggest that functional gap junctions assemble at the interface between DCs and T cells during Ag presentation and that they play an essential role in T cell activation.</p>
]]></description>
<dc:creator><![CDATA[Elgueta, R., Tobar, J. A., Shoji, K. F., De Calisto, J., Kalergis, A. M., Bono, M. R., Rosemblatt, M., Saez, J. C.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0801854</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Gap Junctions at the Dendritic Cell-T Cell Interface Are Key Elements for Antigen-Dependent T Cell Activation]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>284</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>277</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/285?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Altered Thymic Selection and Increased Autoimmunity Caused by Ectopic Expression of DRAK2 during T Cell Development]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/285?rss=1</link>
<description><![CDATA[
<p>Negative regulation of TCR signaling is an important mechanism enforcing immunological self-tolerance to prevent inappropriate activation of T cells and thus the development of autoimmune diseases. The lymphoid-restricted serine/threonine kinase death-associated protein-related apoptotic kinase-2 (DRAK2) raises the TCR activation threshold by targeting TCR-induced calcium mobilization in thymocytes and peripheral T cells and regulates positive thymic selection and peripheral T cell activation. Despite a hypersensitivity of peripheral <I>drak2</I>-deficient T cells, <I>drak2</I>-deficient mice are enigmatically resistant to induced autoimmunity in the model experimental autoimmune encephalomyelitis. To further evaluate the differential role of DRAK2 in central vs peripheral tolerance and to assess its impact on the development of autoimmune diseases, we have generated a transgenic (Tg) mouse strain ectopically expressing DRAK2 via the <I>lck</I> proximal promoter (1017-DRAK2 Tg mice). This transgene led to highest expression levels in double-positive thymocytes that are normally devoid of DRAK2. 1017-DRAK2 Tg mice displayed a reduction of single-positive CD4<sup>+</sup> and CD8<sup>+</sup> thymocytes in context with diminished negative selection in male HY TCR <FONT FACE="arial,helvetica">x</FONT> 1017-DRAK2 Tg mice as well as peripheral T cell hypersensitivity, enhanced susceptibility to experimental autoimmune encephalomyelitis, and spontaneous autoimmunity. These findings suggest that alteration in thymocyte signaling thresholds impacts the sensitivity of peripheral T cell pools.</p>
]]></description>
<dc:creator><![CDATA[Gatzka, M., Newton, R. H., Walsh, C. M.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803530</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Altered Thymic Selection and Increased Autoimmunity Caused by Ectopic Expression of DRAK2 during T Cell Development]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>297</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>285</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/298?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Early Life Exposure to Lipopolysaccharide Suppresses Experimental Autoimmune Encephalomyelitis by Promoting Tolerogenic Dendritic Cells and Regulatory T Cells]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/298?rss=1</link>
<description><![CDATA[
<p>The rising incidence of autoimmune diseases such as multiple sclerosis (MS) in developed countries might be due to a more hygienic environment, particularly during early life. To investigate this concept, we developed a model of neonatal exposure to a common pathogen-associated molecular pattern, LPS, and determined its impact on experimental autoimmune encephalomyelitis (EAE). Mice exposed to LPS at 2 wk of age showed a delayed onset and diminished severity of myelin oligodendrocyte glycoprotein (MOG)-induced EAE, induced at 12 wk, compared with vehicle-exposed animals. Spinal cord transcript levels of <I>CD3</I> and <I>F4/80</I> were lower in LPS- compared with PBS-exposed EAE animals with increased <I>IL-10</I> levels in the LPS-exposed group. Splenic CD11c<sup>+</sup> cells from LPS-exposed animals exhibited reduced MHC class II and CD83 expression but increased levels of CD80 and CD86 both before and during EAE. MOG-treated APC from LPS-exposed animals stimulated less T lymphocyte proliferation but increased expansion of CD4<sup>+</sup>FoxP3<sup>+</sup> T cells compared with APC from PBS-exposed animals. Neuropathological studies disclosed reduced myelin and axonal loss in spinal cords from LPS-exposed compared with PBS-exposed animals with EAE, and this neuroprotective effect was associated with an increased number of CD3<sup>+</sup>FoxP3<sup>+</sup> immunoreactive cells. Analyses of human brain tissue revealed that FoxP3 expression was detected in lymphocytes, albeit reduced in MS compared with non-MS patients&rsquo; brains. These findings support the concept of early-life microbial exposure influencing the generation of neuroprotective regulatory T cells and may provide insights into new immunotherapeutic strategies for MS.</p>
]]></description>
<dc:creator><![CDATA[Ellestad, K. K., Tsutsui, S., Noorbakhsh, F., Warren, K. G., Yong, V. W., Pittman, Q. J., Power, C.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803576</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Early Life Exposure to Lipopolysaccharide Suppresses Experimental Autoimmune Encephalomyelitis by Promoting Tolerogenic Dendritic Cells and Regulatory T Cells]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>309</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>298</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/310?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Vav1 Regulates the Migration and Adhesion of Dendritic Cells]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/310?rss=1</link>
<description><![CDATA[
<p>Dendritic cells (DCs) are the most potent APCs for activating naive T cells, a process facilitated by the ability of immature DCs to mature and home to lymph nodes after encountering an inflammatory stimulus. Proteins involved in cytoskeletal rearrangement play an important role in regulating the adherence and motility of DCs. Vav1, a guanine nucleotide exchange factor for Rho family GTPases, mediates cytoskeletal rearrangement in hematopoietic cells following integrin ligation. We show that Vav1 is not required for the normal maturation of DCs in vitro; however, it is critical for DC binding to fibronectin and regulates the distribution but not the formation of podosomes. We also found that DC Vav1 was an important component of a signaling pathway involving focal adhesion kinase, phospholipase C-2, and ERK1/2 following integrin ligation. Surprisingly, Vav1<sup>&ndash;/&ndash;</sup> DCs had increased rates of migration in vivo compared with wild-type control DCs. In vitro findings show that the presence of adhesive substrates such as fibronectin resulted in inhibition of migration. However, there was less inhibition in the absence of Vav1. These findings suggest that DC migration is negatively regulated by adhesion and integrin-mediated signaling and that Vav1 has a central role in this process.</p>
]]></description>
<dc:creator><![CDATA[Spurrell, D. R., Luckashenak, N. A., Minney, D. C., Chaplin, A., Penninger, J. M., Liwski, R. S., Clements, J. L., West, K. A.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802096</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Vav1 Regulates the Migration and Adhesion of Dendritic Cells]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>318</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>310</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/319?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Clonotype Selection and Composition of Human CD8 T Cells Specific for Persistent Herpes Viruses Varies with Differentiation but Is Stable Over Time]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/319?rss=1</link>
<description><![CDATA[
<p>Protection from reactivation of persistent herpes virus infection is mediated by Ag-specific CD8 T cell responses, which are highly regulated by still poorly understood mechanisms. In this study, we analyzed differentiation and clonotypic dynamics of EBV- and CMV-specific T cells from healthy adults. Although these T lymphocytes included all subsets, from early-differentiated (EM/CD28<sup>pos</sup>) to late-differentiated (EMRA/CD28<sup>neg</sup>) stages, they varied in the sizes/proportions of these subsets. In-depth clonal composition analyses revealed TCR repertoires, which were highly restricted for CMV- and relatively diverse for EBV-specific cells. Virtually all virus-specific clonotypes identified in the EMRA/CD28<sup>neg</sup> subset were also found within the pool of less differentiated "memory" cells. However, striking differences in the patterns of dominance were observed among these subsets, because some clonotypes were selected with differentiation while others were not. Late-differentiated CMV-specific clonotypes were mostly characterized by TCR with lower dependency on CD8 coreceptor interaction. Yet all clonotypes displayed similar functional avidities, suggesting a compensatory role of CD8 in the clonotypes of lower TCR avidity. Importantly, clonotype selection and composition of each virus-specific subset upon differentiation was highly preserved over time, with the presence of the same dominant clonotypes at specific differentiation stages within a period of 4 years. Remarkably, clonotypic distribution was stable not only in late-differentiated but also in less-differentiated T cell subsets. Thus, T cell clonotypes segregate with differentiation, but the clonal composition once established is kept constant for at least several years. These findings reveal novel features of the highly sophisticated control of steady state protective T cell activity in healthy adults.</p>
]]></description>
<dc:creator><![CDATA[Iancu, E. M., Corthesy, P., Baumgaertner, P., Devevre, E., Voelter, V., Romero, P., Speiser, D. E., Rufer, N.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803647</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Clonotype Selection and Composition of Human CD8 T Cells Specific for Persistent Herpes Viruses Varies with Differentiation but Is Stable Over Time]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>331</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>319</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/332?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] The Initial Phase of an Immune Response Functions to Activate Regulatory T Cells]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/332?rss=1</link>
<description><![CDATA[
<p>An early reaction of CD4<sup>+</sup> T lymphocytes to Ag is the production of cytokines, notably IL-2. To detect cytokine-dependent responses, naive Ag-specific T cells were stimulated in vivo and the presence of phosphorylated STAT5 molecules was used to identify the cell populations responding to IL-2. Within hours of T cell priming, IL-2-dependent STAT5 phosphorylation occurred primarily in Foxp3<sup>+</sup> regulatory T cells. In contrast, the Ag-specific T cells received STAT5 signals only after repeated Ag exposure or memory differentiation. Regulatory T cells receiving IL-2 signals proliferated and developed enhanced suppressive activity. These results indicate that one of the earliest events in a T cell response is the activation of endogenous regulatory cells, potentially to prevent autoimmunity.</p>
]]></description>
<dc:creator><![CDATA[O'Gorman, W. E., Dooms, H., Thorne, S. H., Kuswanto, W. F., Simonds, E. F., Krutzik, P. O., Nolan, G. P., Abbas, A. K.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900691</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] The Initial Phase of an Immune Response Functions to Activate Regulatory T Cells]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>339</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>332</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/340?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Human Placenta Expresses and Secretes NKG2D Ligands via Exosomes that Down-Modulate the Cognate Receptor Expression: Evidence for Immunosuppressive Function]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/340?rss=1</link>
<description><![CDATA[
<p>During mammalian pregnancy maternal-fetal tolerance involves a number of immunosuppressive factors produced by placenta. Recently, placenta-derived exosomes have emerged as new immune regulators in the maternal immune tolerance. Exosomes are membrane nanovesicles with defined morphology, which are secreted from endosomal multivesicular bodies (MVB) upon fusion with the plasma membrane. Previously, we reported that the MHC class I chain-related (MIC) proteins A and B, human ligands of the activating NK cell receptor NKG2D, are expressed by placenta, sorted to MVB of syncytiotrophoblast and probably released via MIC-bearing exosomes. In this report, we show that the second family of human NKG2D ligands, the UL-16 binding proteins (ULBP), is also expressed by placenta. Importantly, this expression was not due to placental CMV infection. Immunoelectron microscopy disclosed that ULBP1&ndash;5 are produced and retained in MVB of the syncytiotrophoblast on microvesicles/exosomes. Using human placenta explant cultures and different assays, we demonstrate that exosomes bearing NKG2D ligands are released by human placenta. Isolated placental exosomes carried ULBP1&ndash;5 and MIC on their surface and induced down-regulation of the NKG2D receptor on NK, CD8<sup>+</sup>, and  T cells, leading to reduction of their in vitro cytotoxicity without affecting the perforin-mediated lytic pathway. Release of placental NKG2D ligands via exosomes is an alternative mechanism for generation of bioactive soluble form of these ligands. These findings highlight a role for NKG2D ligand-bearing placental exosomes in the fetal immune escape and support the view of placenta as a unique immunosuppressive organ.</p>
]]></description>
<dc:creator><![CDATA[Hedlund, M., Stenqvist, A.-C., Nagaeva, O., Kjellberg, L., Wulff, M., Baranov, V., Mincheva-Nilsson, L.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803477</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Human Placenta Expresses and Secretes NKG2D Ligands via Exosomes that Down-Modulate the Cognate Receptor Expression: Evidence for Immunosuppressive Function]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>351</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>340</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/352?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Notch Ligands Expressed by Follicular Dendritic Cells Protect Germinal Center B Cells from Apoptosis]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/352?rss=1</link>
<description><![CDATA[
<p>The Notch signaling pathway is one of the most conserved mechanisms to regulate cell fate in many tissues during development and postnatal life. In the immune system, Notch signaling regulates T and B cell development and modulates the differentiation of T and B cells. In this study, we investigated the functional roles of Notch signaling in human B cell differentiation within the germinal center (GC). Notch ligands, Delta-like 1 (Dll1) and Jagged 1 (Jg1), are expressed by follicular dendritic cells (FDC) but not by B cells in the GC, while GC-B cells express the Notch receptors, Notch1 and Notch2. The blockade of Notch signaling pathways using a -secretase inhibitor, DAPT (<I>N</I>-[<I>N</I>-(3,5-difluorophenacetyl-<scp>l</scp>-alanyl)]-<I>S</I>-phenylglycine <I>t</I>-butyl ester), reduces the survival of GC-B cells in the presence of FDC/HK cells. Jg1 has a dominant effect on GC-B cell survival mediated by Notch signaling. Furthermore, Notch cooperates with another anti-apoptotic factor, BAFF/Blys produced by FDC to support GC-B cell growth. Taken together, our data shows the important role of Notch signaling provided by FDC in the survival of GC-B cells in vitro.</p>
]]></description>
<dc:creator><![CDATA[Yoon, S.-O., Zhang, X., Berner, P., Blom, B., Choi, Y. S.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803183</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Notch Ligands Expressed by Follicular Dendritic Cells Protect Germinal Center B Cells from Apoptosis]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>358</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>352</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/359?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Activated Integrin VLA-4 Localizes to the Lamellipodia and Mediates T Cell Migration on VCAM-1]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/359?rss=1</link>
<description><![CDATA[
<p>Lymphocyte migration from blood into lymphoid tissues or to sites of inflammation occurs through interactions between cell surface integrins and their ligands expressed on the vascular endothelium and the extracellular matrix. VLA-4 (<SUB>4</SUB>&beta;<SUB>1</SUB>) is a key integrin in the effective trafficking of lymphocytes. Although it has been well established that integrins undergo functionally significant conformational changes to mediate cell adhesion, there is no mechanistic information that explains how these are dynamically and spatially regulated during lymphocyte polarization and migration. Using dynamic fluorescence resonance energy transfer analysis of a novel VLA-4 FRET sensor under total internal reflection fluorescence microscopy, we show that VLA-4 activation localizes to the lamellipodium in living cells. During T cell migration on VCAM-1, VLA-4 activation concurs with spatial redistribution of chemokine receptor and active Rap1 at the leading edge. Selective inhibition of the activated VLA-4 at the leading edge with a small molecule inhibitor is sufficient to block T cell migration. These data suggest that a subpopulation of activated VLA-4 is mainly localized to the leading edge of polarized human T cells and is critical for T cell migration on VCAM-1.</p>
]]></description>
<dc:creator><![CDATA[Hyun, Y.-M., Chung, H.-L., McGrath, J. L., Waugh, R. E., Kim, M.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803388</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Activated Integrin VLA-4 Localizes to the Lamellipodia and Mediates T Cell Migration on VCAM-1]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>369</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>359</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/370?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Elimination of Immunodominant Epitopes from Multispecific DNA-Based Vaccines Allows Induction of CD8 T Cells That Have a Striking Antiviral Potential]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/370?rss=1</link>
<description><![CDATA[
<p>Immunodominance limits the TCR diversity of specific antiviral CD8 T cell responses elicited by vaccination or infection. To prime multispecific T cell responses, we constructed DNA vaccines that coexpress chimeric, multidomain Ags (with CD8 T cell-defined epitopes of the hepatitis B virus (HBV) surface (S), core (C), and polymerase (Pol) proteins and/or the OVA Ag as stress protein-capturing fusion proteins. Priming of mono- or multispecific, HLA-A*0201- or K<sup>b</sup>-restricted CD8 T cell responses by these DNA vaccines differed. K<sup>b</sup>/OVA<SUB>257&ndash;264</SUB>- and K<sup>b</sup>/S<SUB>190&ndash;197</SUB>-specific CD8 T cell responses did not allow priming of a K<sup>b</sup>/C<SUB>93&ndash;100</SUB>-specific CD8 T cell response in mice immunized with multidomain vaccines. Tolerance to the S- Ag in transgenic Alb/HBs mice (that express large amounts of transgene-encoded S- Ag in the liver) facilitated priming of subdominant, K<sup>b</sup>/C<SUB>93&ndash;100</SUB>-specific CD8 T cell immunity by multidomain Ags. The "weak" (i.e., easily suppressed) K<sup>b</sup>/C<SUB>93&ndash;100</SUB>-specific CD8 T cell response was efficiently elicited by a HBV core Ag-encoding vector in 1.4HBV-S<sup>mut</sup> tg mice (that harbor a replicating HBV genome that produces HBV surface, core, and precore Ag in the liver). K<sup>b</sup>/C<SUB>93&ndash;100</SUB>-specific CD8 T cells accumulated in the liver of vaccinated 1.4HBV-S<sup>mut</sup> transgenic mice where they suppressed HBV replication. Subdominant epitopes in vaccines can hence prime specific CD8 T cell immunity in a tolerogenic milieu that delivers specific antiviral effects to HBV-expressing hepatocytes.</p>
]]></description>
<dc:creator><![CDATA[Riedl, P., Wieland, A., Lamberth, K., Buus, S., Lemonnier, F., Reifenberg, K., Reimann, J., Schirmbeck, R.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900505</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Elimination of Immunodominant Epitopes from Multispecific DNA-Based Vaccines Allows Induction of CD8 T Cells That Have a Striking Antiviral Potential]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>380</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>370</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/381?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] IL-23 Promotes the Production of IL-17 by Antigen-Specific CD8 T Cells in the Absence of IL-12 and Type-I Interferons]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/381?rss=1</link>
<description><![CDATA[
<p>In contrast to CD4 T cells, CD8 T cells inherently differentiate into IFN--producing effectors. Accordingly, while generation of IFN--producing Th1 CD4 T cells was profoundly impaired in mice deficient for both type-I IFN and IL-12 signaling in response to infection with <I>Listeria monocytogenes</I>, generation of Ag-specific, IFN--producing CD8 T cells was unimpaired. However, a fraction of these CD8 T cells also produced IL-17 in an IL-23-dependent manner. Furthermore, the addition of IL-23 in vitro was sufficient for some naive CD8 T cells to differentiate into IFN-/IL-17 dual-producing cells and was associated with increased expression of ROR-t and ROR-. Addition of IL-6 and TGF-&beta; to IL-23 further augmented ROR-t and ROR- expression and suppressed Eomes expression, thereby enhancing IL-17 production by CD8 T cells. A loss of cytotoxic function accompanied the production of IL-17, as the addition of IL-6 and TGF-&beta; resulted in a marked reduction of granzyme B and perforin expression. Thus, CD8 T cells retain sufficient plasticity to respond to environmental cues and can acquire additional effector functions in response to their environmental context.</p>
]]></description>
<dc:creator><![CDATA[Curtis, M. M., Way, S. S., Wilson, C. B.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900939</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] IL-23 Promotes the Production of IL-17 by Antigen-Specific CD8 T Cells in the Absence of IL-12 and Type-I Interferons]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>387</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>381</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/388?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Increased Intracellular, Cell Surface, and Secreted Inducible Heat Shock Protein 70 Responses Are Triggered during the Monocyte to Dendritic Cell (DC) Transition by Cytokines Independently of Heat Stress and Infection and May Positively Regulate DC Growth]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/388?rss=1</link>
<description><![CDATA[
<p>Physiologic triggers and functional consequences of endogenous heat shock protein (HSP) responses in dendritic cells (DC) are poorly defined. In this study, we show that even in the absence of heat stress and infection, a specific cohort of DC/proinflammatory cytokines (IL-4-IL-13/IL-6/GM-CSF) institutes an enhanced inducible (i)HSP70 intracellular and extracellular response in human monocyte-derived DC, especially during the monocyte to DC transition. Interestingly, whereas heat stress alone initiated an intracellular iHSP70 response in monocyte DC precursors, it did not promote cell surface or secreted iHSP70 responses, both of which were induced by cytokines independently of heat. The cytokine-induced iHSP70 response, which did not occur in lymphocytes, or monocytes-macrophages generated with M-CSF, was instituted within 48 h of cytokine exposure, and peaked upon commitment to DC growth at 72 h. Although a return to baseline levels was noted after this period, a distinct rise in iHSP70 occurred again during terminal DC maturation. Chemical inhibition of the iHSP70 response with either triptolide or KNK-437 was coupled with inhibition of DC differentiation and yielded cells displaying features of monocytes-macrophages. Exogenously supplied riHSP70 amplified events associated with cytokine-advanced DC differentiation/maturation, most notably the up-regulation of antiapoptotic proteins (Bcl-x<SUB>L</SUB>). Engaging the HSP receptor CD40 with CD40L produced identical results as extracellular riHSP70, and, moreover, an enhanced iHSP70 response. Thus, distinct iHSP70 and HSP receptor-mediated responses are triggered by cytokines irrespective of heat stress and infection in monocyte-derived DC and may function to positively regulate monocyte-derived DC, especially during critical periods of their growth.</p>
]]></description>
<dc:creator><![CDATA[Martin, C. A., Kurkowski, D. L., Valentino, A. M., Santiago-Schwarz, F.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802688</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] Increased Intracellular, Cell Surface, and Secreted Inducible Heat Shock Protein 70 Responses Are Triggered during the Monocyte to Dendritic Cell (DC) Transition by Cytokines Independently of Heat Stress and Infection and May Positively Regulate DC Growth]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>399</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>388</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/400?rss=1">
<title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] CD11c+CD8{alpha}+ Dendritic Cells Promote Protective Immunity to Respiratory Infection with Bordetella pertussis]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/400?rss=1</link>
<description><![CDATA[
<p>CD11c<sup>+</sup>CD8<sup>+</sup> and CD103<sup>+</sup> dendritic cells (DC) have been shown to promote regulatory T cell responses and mediate tolerance in the gastrointestinal tract. These cells have also been identified in the lung, but their role in immunity to respiratory tract infection is not clear. In this study, we have used a murine model of infection with <I>Bordetella pertussis</I> to examine the function of DC subtypes in protective immunity in the lungs. We found a dramatic increase in the numbers of CD11c<sup>+</sup>CD8<sup>+</sup> DC in the cervical lymph nodes within 4 h of challenge with <I>B. pertussis</I> and these DC could acquire particulate Ag from the upper respiratory tract. CD11c<sup>+</sup>CD8<sup>+</sup> DC also infiltrated the lung with a peak 7 days after <I>B. pertussis</I> challenge. The infiltrating CD11c<sup>+</sup>CD8<sup>+</sup> DC expressed MHC, costimulatory and activation markers indicative of mature DC. The CD11c<sup>+</sup>CD8<sup>+</sup> DC in the cervical lymph nodes expressed IL-4 and IL-10 and lower levels of IFN-, but in the lungs expressed predominantly IFN-. Depletion of CD8<sup>+</sup> cells early in infection attenuated Th1 responses in the lungs and significantly reduced bacterial clearance. Conversely, transfer of FLT3 ligand (FL)-expanded CD11c<sup>+</sup>CD8<sup>+</sup> DC enhanced bacterial clearance, whereas GM-CSF-expanded conventional DC had no effect. The numbers of CD11c<sup>+</sup>CD8<sup>+</sup>CD103<sup>+</sup> cells were also increased during the early phase of infection. Blocking CD103 function caused a significant delay in bacterial clearance and a reduction in cellular infiltration into the lungs. These findings demonstrate that CD11c<sup>+</sup>CD8<sup>+</sup> and CD11c<sup>+</sup>CD103<sup>+</sup>DC play a protective role in mediating immunity to <I>B. pertussis</I> infection in the respiratory tract.</p>
]]></description>
<dc:creator><![CDATA[Dunne, P. J., Moran, B., Cummins, R. C., Mills, K. H. G.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900169</dc:identifier>
<dc:title><![CDATA[[CELLULAR IMMUNOLOGY AND IMMUNE REGULATION] CD11c+CD8{alpha}+ Dendritic Cells Promote Protective Immunity to Respiratory Infection with Bordetella pertussis]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>410</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>400</prism:startingPage>
<prism:section>CELLULAR IMMUNOLOGY AND IMMUNE REGULATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/411?rss=1">
<title><![CDATA[[MOLECULAR AND STRUCTURAL IMMUNOLOGY] Neutrophil Elastase Represses IL-8/CXCL8 Synthesis in Human Airway Smooth Muscle Cells through Induction of NF-{kappa}B Repressing Factor]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/411?rss=1</link>
<description><![CDATA[
<p>NF-B repressing factor (NRF), a nuclear inhibitor of NF-B, is constitutively expressed and is implicated in the basal silencing of specific NF-B targeting genes, including <I>IFN</I>-&beta;, <I>IL-8/CXCL8</I>, and <I>iNOS</I>. Little is known about the regulation of NRF and its role in response to stimuli. Airway smooth muscle (ASM) is a rich source of inflammatory mediators that may regulate the development and progression of airway inflammation. We have previously reported that NE activates NF-B in primary human ASM (hASM), leading to induction of TGF-&beta;1. In this study, we describe that, instead of inducing the NF-B response gene <I>IL-8/CXCL8</I>, NE suppressed IL-8/CXCL8 release and mRNA expression in hASM cells. Transcriptional blockade studies using actinomycin D revealed a similar degradation rate of IL-8/CXCL8 mRNA in the presence or absence of NE, suggesting an involvement at the transcription level. Mechanistically, the NE repressive effect was mediated by inducing NRF, as shown by RT-PCR and Western blotting, which was subsequently recruited to the native <I>IL-8/CXCL8</I> promoter leading to removal of RNA polymerase II from the promoter, as demonstrated by chromatin immunoprecipitation assays. Knockdown of NRF by small interfering RNA prevented NE-induced suppression of IL-8/CXCL8 expression. In contrast, NE did not induce NRF expression in A549 and Beas-2B cells, where NE only stimulates NF-B activation and IL-8/CXCL8 induction. Forced expression of NRF in A549 cells by an NRF expression plasmid suppressed IL-8/CXCL8 expression. Hence, we describe a novel negative regulatory mechanism of NE-induced NRF, which is restricted to hASM and mediates the suppression of IL-8/CXCL8 expression.</p>
]]></description>
<dc:creator><![CDATA[Ho, S.-C., Lee, K.-Y., Chan, Y.-F., Kuo, L.-W., Ito, K., Adcock, I. M., Chen, B.-C., Sheu, J.-R., Lin, C.-H., Kuo, H.-P.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803729</dc:identifier>
<dc:title><![CDATA[[MOLECULAR AND STRUCTURAL IMMUNOLOGY] Neutrophil Elastase Represses IL-8/CXCL8 Synthesis in Human Airway Smooth Muscle Cells through Induction of NF-{kappa}B Repressing Factor]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>420</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>411</prism:startingPage>
<prism:section>MOLECULAR AND STRUCTURAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/421?rss=1">
<title><![CDATA[[MOLECULAR AND STRUCTURAL IMMUNOLOGY] Structural Basis for Proteolytic Specificity of the Human Apoptosis-Inducing Granzyme M]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/421?rss=1</link>
<description><![CDATA[
<p>Granzyme M (GzmM), a unique serine protease constitutively expressed in NK cells, is important for granule-mediated cytolysis and can induce rapid caspase-dependent apoptosis of tumor cells. However, few substrates of GzmM have been reported to date, and the mechanism by which this enzyme recognizes and hydrolyzes substrates is unknown. To provide structural insights into the proteolytic specificity of human GzmM (hGzmM), crystal structures of wild-type hGzmM, the inactive D86N-GzmM mutant with bound peptide substrate, and the complexes with a catalytic product and with a tetrapeptide chloromethylketone inhibitor were solved to 1.96 &Aring;, 2.30 &Aring;, 2.17 &Aring; and 2.70 &Aring;, respectively. Structure-based mutagenesis revealed that the N terminus and catalytic triad of hGzmM are most essential for proteolytic function. In particular, D86N-GzmM was found to be an ideal inactive enzyme for functional studies. Structural comparisons indicated a large conformational change of the L3 loop upon substrate binding, and suggest this loop mediates the substrate specificity of hGzmM. Based on the complex structure of GzmM with its catalytic product, a tetrapeptide chloromethylketone inhibitor was designed and found to specifically block the catalytic activity of hGzmM.</p>
]]></description>
<dc:creator><![CDATA[Wu, L., Wang, L., Hua, G., Liu, K., Yang, X., Zhai, Y., Bartlam, M., Sun, F., Fan, Z.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803088</dc:identifier>
<dc:title><![CDATA[[MOLECULAR AND STRUCTURAL IMMUNOLOGY] Structural Basis for Proteolytic Specificity of the Human Apoptosis-Inducing Granzyme M]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>429</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>421</prism:startingPage>
<prism:section>MOLECULAR AND STRUCTURAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/430?rss=1">
<title><![CDATA[[MOLECULAR AND STRUCTURAL IMMUNOLOGY] Structural Bases for the Affinity-Driven Selection of a Public TCR against a Dominant Human Cytomegalovirus Epitope]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/430?rss=1</link>
<description><![CDATA[
<p>Protective T cell responses elicited along chronic human CMV (HCMV) infections are sometimes dominated by CD8 T cell clones bearing highly related or identical public TCR in unrelated individuals. To understand the principles that guide emergence of these public T cell responses, we have performed structural, biophysical, and functional analyses of an immunodominant public TCR (RA14) directed against a major HLA-A*0201-restricted HCMV Ag (pp65<SUB>495&ndash;503</SUB>) and selected in vivo from a diverse repertoire after chronic stimulations. Unlike the two immunodominant public TCRs crystallized so far, which focused on one peptide hotspot, the HCMV-specific RA14 TCR interacts with the full array of available peptide residues. The conservation of some peptide-MHC complex-contacting amino acids by lower-affinity TCRs suggests a shared TCR-peptide-MHC complex docking mode and supports an Ag-driven selection of optimal TCRs. Therefore, the emergence of a public TCR of an oligoclonal Ag-specific response after repeated viral stimulations is based on a receptor displaying a high structural complementarity with the entire peptide and focusing on three peptide hotspots. This highlights key parameters underlying the selection of a protective T cell response against HCMV infection, which remains a major health issue in patients undergoing bone marrow transplantation.</p>
]]></description>
<dc:creator><![CDATA[Gras, S., Saulquin, X., Reiser, J.-B., Debeaupuis, E., Echasserieau, K., Kissenpfennig, A., Legoux, F., Chouquet, A., Le Gorrec, M., Machillot, P., Neveu, B., Thielens, N., Malissen, B., Bonneville, M., Housset, D.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900556</dc:identifier>
<dc:title><![CDATA[[MOLECULAR AND STRUCTURAL IMMUNOLOGY] Structural Bases for the Affinity-Driven Selection of a Public TCR against a Dominant Human Cytomegalovirus Epitope]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>437</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>430</prism:startingPage>
<prism:section>MOLECULAR AND STRUCTURAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/438?rss=1">
<title><![CDATA[[MOLECULAR AND STRUCTURAL IMMUNOLOGY] The Transmembrane E3 Ligase GRAIL Ubiquitinates and Degrades CD83 on CD4 T Cells]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/438?rss=1</link>
<description><![CDATA[
<p>Ubiquitination of eukaryotic proteins regulates a broad range of cellular processes, including T cell activation and tolerance. We have previously demonstrated that GRAIL (gene related to anergy in lymphocytes), a transmembrane RING finger ubiquitin E3 ligase, initially described as induced during the induction of CD4 T cell anergy, is also expressed in resting CD4 T cells. In this study, we show that GRAIL can down-modulate the expression of CD83 (previously described as a cell surface marker for mature dendritic cells) on CD4 T cells. GRAIL-mediated down-modulation of CD83 is dependent on an intact GRAIL extracellular protease-associated domain and an enzymatically active cytosolic RING domain, and proceeds via the ubiquitin-dependent 26S proteosome pathway. Ubiquitin modification of lysine residues K168 and K183, but not K192, in the cytoplasmic domain of CD83 was shown to be necessary for GRAIL-mediated degradation of CD83. Reduced CD83 surface expression levels were seen both on anergized CD4 T cells and following GRAIL expression by retroviral transduction, whereas GRAIL knock-down by RNA interference in CD4 T cells resulted in elevated CD83 levels. Furthermore, CD83 expression on CD4 T cells contributes to T cell activation as a costimulatory molecule. This study supports the novel mechanism of ubiquitination by GRAIL, identifies CD83 as a substrate of GRAIL, and ascribes a role for CD83 in CD4 T cell activation.</p>
]]></description>
<dc:creator><![CDATA[Su, L. L., Iwai, H., Lin, J. T., Fathman, C. G.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900204</dc:identifier>
<dc:title><![CDATA[[MOLECULAR AND STRUCTURAL IMMUNOLOGY] The Transmembrane E3 Ligase GRAIL Ubiquitinates and Degrades CD83 on CD4 T Cells]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>444</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>438</prism:startingPage>
<prism:section>MOLECULAR AND STRUCTURAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/445?rss=1">
<title><![CDATA[[MOLECULAR AND STRUCTURAL IMMUNOLOGY] The Coding ECP 434(G>C) Gene Polymorphism Determines the Cytotoxicity of ECP but Has Minor Effects on Fibroblast-Mediated Gel Contraction and No Effect on RNase Activity]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/445?rss=1</link>
<description><![CDATA[
<p>Eosinophil cationic protein (ECP) is a secretory protein of the eosinophil granulocyte, a cell involved in innate immunity. Functional studies have implicated ECP in numerous processes, such as tissue remodeling in allergic inflammation and cytotoxicity toward a variety of pathogens. Recent genetic studies have suggested that the ECP 434(G&gt;C) polymorphism resulting in an arg97thr substitution would alter the function of ECP in vivo. Functional (in vitro) studies of ECP up until now have either been conducted with native preparations containing an unknown mixture of the ECP<sup>97arg</sup> and ECP<sup>97thr</sup> variants, or with recombinant proteins. Therefore, we have now for the first time extracted the native ECP<sup>97arg</sup> and ECP<sup>97thr</sup> variants from healthy blood donors and tested them functionally in vitro. Our results show that the arg97thr shift dramatically alters the cytotoxic capacity of ECP in vitro; the tested ECP<sup>97arg</sup> variants were cytotoxic toward the small-cell lung cancer cell line NCI-H69, whereas ECP<sup>97thr</sup> was noncytotoxic. RNase activity was unaffected by the arg97thr substitution. Both ECP<sup>97arg</sup> and ECP<sup>97thr</sup> stimulated fibroblast-mediated collagen gel contraction, an experimental model, which depicts wound healing, in a dose-dependent manner. In conclusion, our results demonstrate that the ECP 434(G&gt;C) gene polymorphism affects the functional properties of native ECP, but also that there is a dissociation between different biological activities; the arg97thr substitution impairs the cytotoxic potential of ECP but less the gel contraction and not at all the RNase activity.</p>
]]></description>
<dc:creator><![CDATA[Rubin, J., Zagai, U., Blom, K., Trulson, A., Engstrom, A., Venge, P.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803912</dc:identifier>
<dc:title><![CDATA[[MOLECULAR AND STRUCTURAL IMMUNOLOGY] The Coding ECP 434(G>C) Gene Polymorphism Determines the Cytotoxicity of ECP but Has Minor Effects on Fibroblast-Mediated Gel Contraction and No Effect on RNase Activity]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>451</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>445</prism:startingPage>
<prism:section>MOLECULAR AND STRUCTURAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/452?rss=1">
<title><![CDATA[[IMMUNOGENETICS] Antibodies in a Heavy Chain Knock-In Mouse Exhibit Characteristics of Early Heavy Chain Rearrangement]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/452?rss=1</link>
<description><![CDATA[
<p>Studies in autoantibody transgenic mice have demonstrated receptor editing rearrangements at Ab H and L chain loci. However, the physiologic role of H chain editing (V<SUB>H</SUB> replacement and rearrangement on the second allele) has been called into question. It is unclear if additional rounds of H chain rearrangement are driven by BCR specificity. In this study, we analyze the manner in which B cells undergo additional H chain rearrangements in an anti-DNA H chain knock-in mouse, B6.56R. We find that rearrangements in 56R<sup>+</sup> B cells tend to involve the D gene locus on both alleles and the most J<SUB>H</SUB>-proximal V<SUB>H</SUB> gene segments on the endogenous allele. As a result, some B cells exhibit V(D)J rearrangements on both H chain alleles, yet allelic exclusion is tightly maintained in mature 56R B cells. As B cells mature, a higher proportion expresses the nontransgenic H chain allele. Rearrangements on both H chain alleles exhibit junctional diversity consistent with TdT-mediated N-addition, and TdT RNA is expressed exclusively at the pro-B cell stage in B6.56R. Collectively, these findings favor a single, early window of H chain rearrangement in B6.56R that precedes the expression of a functional BCR. B cells that happen to successfully rearrange another H chain may be favored in the periphery.</p>
]]></description>
<dc:creator><![CDATA[Yunk, L., Meng, W., Cohen, P. L., Eisenberg, R. A., Luning Prak, E. T.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0804060</dc:identifier>
<dc:title><![CDATA[[IMMUNOGENETICS] Antibodies in a Heavy Chain Knock-In Mouse Exhibit Characteristics of Early Heavy Chain Rearrangement]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>461</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>452</prism:startingPage>
<prism:section>IMMUNOGENETICS</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/462?rss=1">
<title><![CDATA[[IMMUNOGENETICS] Identification of a Major Susceptibility Locus for Lethal Graft-versus-Host Disease in MHC-Matched Mice]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/462?rss=1</link>
<description><![CDATA[
<p>Graft-vs-host disease (GVHD) is the major cause of morbidity and mortality after allogeneic hemopoietic cell transplantation. From a genetic perspective, GVHD is a complex phenotypic trait. Although it is understood that susceptibility results from interacting polymorphisms of genes encoding histocompatibility Ags and immune regulatory molecules, a detailed and integrative understanding of the genetic background underlying GVHD remains lacking. To gain insight regarding these issues, we performed a forward genetic study. A MHC-matched mouse model was used in which irradiated recipient BALB.K and B10.BR mice demonstrate differential susceptibility to lethal GHVD when transplanted using AKR/J donors. Assessment of GVHD in (B10.BR <FONT FACE="arial,helvetica">x</FONT> BALB.K)F<SUB>1</SUB> mice revealed that susceptibility is a dominant trait and conferred by deleterious alleles from the BALB.K strain. To identify the alleles responsible for GVHD susceptibility, a genome-scanning approach was taken using (B10.BR <FONT FACE="arial,helvetica">x</FONT> BALB.K)F<SUB>1</SUB> <FONT FACE="arial,helvetica">x</FONT> B10.BR backcross mice as recipients. A major susceptibility locus, termed the <I>Gvh1</I> locus, was identified on chromosome 16 using linkage analysis (logarithm of the odds, 9.1). A second locus was found on chromosome 13, named <I>Gvh2</I>, which had additive but protective effects. Further identification of <I>Gvh</I> genes by positional cloning may yield new insight into genetic control mechanisms regulating GVHD and potentially reveal novel approaches for effective GVHD therapy.</p>
]]></description>
<dc:creator><![CDATA[Cao, T. M., Lazzeroni, L. C., Tsai, S., Pang, W. W., Kao, A., Camp, N. J., Thomas, A., Shizuru, J. A.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900454</dc:identifier>
<dc:title><![CDATA[[IMMUNOGENETICS] Identification of a Major Susceptibility Locus for Lethal Graft-versus-Host Disease in MHC-Matched Mice]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>469</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>462</prism:startingPage>
<prism:section>IMMUNOGENETICS</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/470?rss=1">
<title><![CDATA[[HOST DEFENSE] Immunization with the DNA-Encoding N-Terminal Domain of Proteophosphoglycan of Leishmania donovani Generates Th1-Type Immunoprotective Response against Experimental Visceral Leishmaniasis]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/470?rss=1</link>
<description><![CDATA[
<p><I>Leishmania</I> produce several types of mucin-like glycoproteins called proteophosphoglycans (PPGs) which exist as secretory as well as surface-bound forms in both promastigotes and amastigotes. The structure and function of PPGs have been reported to be species and stage specific as in the case of <I>Leishmania major</I> and <I>Leishmania mexicana</I>; there has been no such information available for <I>Leishmania donovani</I>. We have recently demonstrated that PPG is differentially expressed in sodium stibogluconate-sensitive and -resistant clinical isolates of <I>L. donovani</I>. To further elucidate the structure and function of the <I>ppg</I> gene of <I>L. donovani</I>, a partial sequence of its N-terminal domain of 1.6 kb containing the majority of antigenic determinants, was successfully cloned and expressed in prokaryotic as well as mammalian cells. We further evaluated the DNA-encoding N-terminal domain of the <I>ppg</I> gene as a vaccine in golden hamsters (<I>Mesocricetus auratus</I>) against the <I>L. donovani</I> challenge. The prophylactic efficacy to the tune of ~80% was observed in vaccinated hamsters and all of them could survive beyond 6 mo after challenge. The efficacy was supported by a surge in inducible NO synthase, IFN-, TNF-, and IL-12 mRNA levels along with extreme down-regulation of TGF-&beta;, IL-4, and IL-10. A rise in the level of <I>Leishmania</I>-specific IgG2 was also observed which was indicative of enhanced cellular immune response. The results suggest the N-terminal domain of <I>L. donovani ppg</I> as a potential DNA vaccine against visceral leishmaniasis.</p>
]]></description>
<dc:creator><![CDATA[Samant, M., Gupta, R., Kumari, S., Misra, P., Khare, P., Kushawaha, P. K., Sahasrabuddhe, A. A., Dube, A.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900265</dc:identifier>
<dc:title><![CDATA[[HOST DEFENSE] Immunization with the DNA-Encoding N-Terminal Domain of Proteophosphoglycan of Leishmania donovani Generates Th1-Type Immunoprotective Response against Experimental Visceral Leishmaniasis]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>479</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>470</prism:startingPage>
<prism:section>HOST DEFENSE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/480?rss=1">
<title><![CDATA[[HOST DEFENSE] Multivalent Binding of Carbohydrates by the Human {alpha}-Defensin, HD5]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/480?rss=1</link>
<description><![CDATA[
<p>Four of the six human -defensins (human neutrophil peptides 1&ndash;3 and human -defensin 5; HD5) have a lectin-like ability to bind glycosylated proteins. Using HD5 as a model, we applied surface plasmon resonance techniques to gain insights into this property. HD5 bound natural glycoproteins &gt; neoglycoproteins based on BSA &gt; nonglycosylated BSA &gt;&gt; free sugars. The affinity of HD5 for simple sugars covalently bound to BSA was orders of magnitude greater than its affinity for the same sugars in solution. The affinity of HD5 for protein-bound carbohydrates resulted from multivalent interactions which may also involve noncarbohydrate residues of the proteins. HD5 showed concentration-dependent self-association that began at submicromolar concentrations and proceeded to dimer and tetramer formation at concentrations below 5 &micro;M. The (R9A, R28A) and (R13A, R32A) analogs of HD5 showed greatly reduced self-association as well as minimal binding to BSA and to BSA-affixed sugars. From this and other evidence, we conclude that the extensive binding of HD5 to (neo)glycoproteins results from multivalent nonspecific interactions of individual HD5 molecules with carbohydrate and noncarbohydrate moieties of the target molecule and that the primary binding events are magnified and enhanced by subsequent in situ assembly and oligomerization of HD5. Self-association and multivalent binding may play integral roles in the ability of HD5 to protect against infections caused by viruses and other infectious agents.</p>
]]></description>
<dc:creator><![CDATA[Lehrer, R. I., Jung, G., Ruchala, P., Andre, S., Gabius, H. J., Lu, W.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900244</dc:identifier>
<dc:title><![CDATA[[HOST DEFENSE] Multivalent Binding of Carbohydrates by the Human {alpha}-Defensin, HD5]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>490</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>480</prism:startingPage>
<prism:section>HOST DEFENSE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/491?rss=1">
<title><![CDATA[[HOST DEFENSE] Downstream Signals for MyD88-Mediated Phagocytosis of Borrelia burgdorferi Can Be Initiated by TRIF and Are Dependent on PI3K]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/491?rss=1</link>
<description><![CDATA[
<p>We previously have shown that MyD88 is important for uptake of <I>Borrelia burgdorferi</I> by bone marrow derived macrophages (BMDMs). The mechanism by which MyD88 is involved in uptake of <I>B. burgdorferi</I> is currently is not well characterized. Here, we report that MyD88-mediated defect in the phagocytosis of <I>B. burgdorferi</I> can be complemented by TLR3/Toll/IL-1R domain-containing adaptor-inducing IFN-&beta; (TRIF) activation in BMDMs from MyD88<sup>&ndash;/&ndash;</sup> mice. This effect of TLR3/TRIF activation was not due to its induction of type I IFNs, suggesting instead a convergence of signaling pathways downstream of MyD88 and TRIF. To characterize signaling pathways involved in MyD88-mediated phagocytosis of <I>B. burgdorferi</I>, BMDMs were treated with specific inhibitors of MAPK, protein kinase C, JAK/STAT, or PI3K. Only inhibition of PI3K resulted in a significant decrease of <I>B. burgdorferi</I> uptake. Consistent with this, <I>B. burgdorferi</I> activation of MyD88 or TLR3/TRIF signaling resulted in increased activity of PI3K. Additionally, association of <I>B. burgdorferi</I> with actin-related protein (Arp2/3) complexes, which facilitate actin rearrangements during phagocytosis, was similarly reduced in MyD88<sup>&ndash;/&ndash;</sup> BMDMs and in BMDMs treated with a PI3K inhibitor. Taken together, these findings define an essential pathway whereby downstream signals from MyD88 or TRIF converge on PI3K, which triggers actin polymerization to initiate the phagocytosis of <I>B. burgdorferi</I>.</p>
]]></description>
<dc:creator><![CDATA[Shin, O. S., Miller, L. S., Modlin, R. L., Akira, S., Uematsu, S., Hu, L. T.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900724</dc:identifier>
<dc:title><![CDATA[[HOST DEFENSE] Downstream Signals for MyD88-Mediated Phagocytosis of Borrelia burgdorferi Can Be Initiated by TRIF and Are Dependent on PI3K]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>498</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>491</prism:startingPage>
<prism:section>HOST DEFENSE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/499?rss=1">
<title><![CDATA[[HOST DEFENSE] The Cannabinoid Receptor 2 Is Critical for the Host Response to Sepsis]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/499?rss=1</link>
<description><![CDATA[
<p>Leukocyte function can be modulated through the cannabinoid receptor 2 (CB2R). Using a cecal ligation and puncture (CLP) model of sepsis, we examined the role of the CB2R during the immune response to an overwhelming infection. CB2R-knock out (KO) mice showed decreased survival as compared with wild-type mice. CB2R-KO mice also had increased serum IL-6 and bacteremia. Twenty-four hours after CLP, the CB2R-deficient mice had increased lung injury. Additionally, CB2R-deficiency led to increased neutrophil recruitment, decreased neutrophil activation, and decreased p38 activity at the site of infection. Consistent with a novel role for CB2R in sepsis, CB2R-agonist treatment in wild-type mice increased the mean survival time in response to CLP. Treatment with CB2R-agonist also decreased serum IL-6 levels, bacteremia, and damage to the lungs compared with vehicle-treated mice. Finally, the CB2R agonist decreased neutrophil recruitment, while increasing neutrophil activation and p38 activity at the site of infection compared with vehicle-treated mice. These data suggest that CB2R is a critical regulator of the immune response to sepsis and may be a novel therapeutic target.</p>
]]></description>
<dc:creator><![CDATA[Tschop, J., Kasten, K. R., Nogueiras, R., Goetzman, H. S., Cave, C. M., England, L. G., Dattilo, J., Lentsch, A. B., Tschop, M. H., Caldwell, C. C.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900203</dc:identifier>
<dc:title><![CDATA[[HOST DEFENSE] The Cannabinoid Receptor 2 Is Critical for the Host Response to Sepsis]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>505</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>499</prism:startingPage>
<prism:section>HOST DEFENSE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/506?rss=1">
<title><![CDATA[[HOST DEFENSE] Soluble TLR2 Reduces Inflammation without Compromising Bacterial Clearance by Disrupting TLR2 Triggering]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/506?rss=1</link>
<description><![CDATA[
<p>TLR overactivation may lead to end organ damage and serious acute and chronic inflammatory conditions. TLR responses must therefore be tightly regulated to control disease outcomes. We show in this study the ability of the soluble form of TLR2 (sTLR2) to regulate proinflammatory responses, and demonstrate the mechanisms underlying sTLR2 regulatory capacity. Cells overexpressing sTLR2, or stimulated in the presence of the sTLR2 protein, are hyporesponsive to TLR2 ligands. Regulation was TLR2 specific, and affected NF-B activation, phagocytosis, and superoxide production. Natural sTLR2-depleted serum rendered leukocytes hypersensitive to TLR2-mediated stimulation. Mice administered sTLR2 together with Gram-positive bacteria-derived components showed lower peritoneal levels of the neutrophil (PMN) chemoattractant, keratinocyte-derived chemokine; lower PMN numbers; and a reduction in late apoptotic PMN. Mononuclear cell recruitment remained unaffected, and endogenous peritoneal sTLR2 levels increased. Notably, the capacity of sTLR2 to modulate acute inflammatory parameters did not compromise the ability of mice to clear live Gram-positive bacteria-induced infection. Mechanistically, sTLR2 interfered with TLR2 mobilization to lipid rafts for signaling, acted as a decoy microbial receptor, and disrupted the interaction of TLR2 with its coreceptor, CD14, by associating with CD14. These findings establish sTLR2 as a regulator of TLR2-mediated inflammatory responses, capable of blunting immune responses without abrogating microbial recognition and may inform the design of novel therapeutics against acute and chronic inflammatory conditions.</p>
]]></description>
<dc:creator><![CDATA[Raby, A.-C., Le Bouder, E., Colmont, C., Davies, J., Richards, P., Coles, B., George, C. H., Jones, S. A., Brennan, P., Topley, N., Labeta, M. O.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802909</dc:identifier>
<dc:title><![CDATA[[HOST DEFENSE] Soluble TLR2 Reduces Inflammation without Compromising Bacterial Clearance by Disrupting TLR2 Triggering]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>517</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>506</prism:startingPage>
<prism:section>HOST DEFENSE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/518?rss=1">
<title><![CDATA[[HOST DEFENSE] Generation of Protective T Cell-Independent Antiviral Antibody Responses in SCID Mice Reconstituted with Follicular or Marginal Zone B Cells]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/518?rss=1</link>
<description><![CDATA[
<p>B cells generated in the bone marrow of adult mice enter the periphery as transitional B cells and subsequently differentiate into one of two phenotypically and functionally distinct subsets, marginal zone (MZ) or follicular (Fo) B cells. Recent reports indicate, however, that in response to environmental cues, such as lymphopenia, mature Fo B cells can change to display phenotypic markers characteristic of MZ B cells. Previously, we found that splenic B cells transferred to SCID mice responded to polyoma virus (PyV) infection with T cell-independent (TI) IgM and IgG secretion, reducing the viral load and protecting mice from the lethal effect of the infection. The contribution of MZ and Fo B cell subsets to this antiviral TI-2 response, however, has not been addressed. In this study, we show that both sort-purified MZ and Fo B cells generate protective TI Ab responses to PyV infection when transferred into SCID mice. Moreover, the transferred Fo B cells in the spleens of the PyV-infected SCID mice change phenotype, with many of them displaying MZ B cell characteristics. These findings demonstrate the plasticity of the B cell subsets in virus-infected hosts and show for the first time that B cells derived exclusively from Fo B cells can effectively function in antiviral TI-2 responses.</p>
]]></description>
<dc:creator><![CDATA[Guay, H. M., Mishra, R., Garcea, R. L., Welsh, R. M., Szomolanyi-Tsuda, E.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900068</dc:identifier>
<dc:title><![CDATA[[HOST DEFENSE] Generation of Protective T Cell-Independent Antiviral Antibody Responses in SCID Mice Reconstituted with Follicular or Marginal Zone B Cells]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>523</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>518</prism:startingPage>
<prism:section>HOST DEFENSE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/524?rss=1">
<title><![CDATA[[HOST DEFENSE] Follicular Dendritic Cells Activate HIV-1 Replication in Monocytes/Macrophages through a Juxtacrine Mechanism Mediated by P-Selectin Glycoprotein Ligand 1]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/524?rss=1</link>
<description><![CDATA[
<p>Follicular dendritic cells (FDCs) are located in the lymphoid follicles of secondary lymphoid tissues and play a pivotal role in the selection of memory B lymphocytes within the germinal center, a major site for HIV-1 infection. Germinal centers are composed of highly activated B cells, macrophages, CD4<sup>+</sup>T cells, and FDCs. However, the physiological role of FDCs in HIV-1 replication remains largely unknown. We demonstrate in our current study that FDCs can efficiently activate HIV-1 replication in latently infected monocytic cells via an intercellular communication network mediated by the P-selectin/P-selectin glycoprotein ligand 1 (PSGL-1) interaction. Upon coculture with FDCs, HIV-1 replication was significantly induced in infected monocytic cell lines, primary monocytes, or macrophages. These cocultures were found to synergistically induce the expression of P-selectin in FDCs via NF-B activation and its cognate receptor PSGL-1 in HIV-1-infected cells. Consistent with this observation, we find that this response is significantly blocked by antagonistic Abs against PSGL-1 and almost completely inhibited by PSGL-1 small interfering RNA. Moreover, a selective inhibitor for Syk, which is a downstream effector of PSGL-1, blocked HIV-1 replication in our cultures. We have thus elucidated a novel regulatory mechanism in which FDCs are a potent positive bystander that facilitates HIV-1 replication in adjacent infected monocytic cells via a juxtacrine signaling mechanism.</p>
]]></description>
<dc:creator><![CDATA[Ohba, K., Ryo, A., Dewan, Md. Z., Nishi, M., Naito, T., Qi, X., Inagaki, Y., Nagashima, Y., Tanaka, Y., Okamoto, T., Terashima, K., Yamamoto, N.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900371</dc:identifier>
<dc:title><![CDATA[[HOST DEFENSE] Follicular Dendritic Cells Activate HIV-1 Replication in Monocytes/Macrophages through a Juxtacrine Mechanism Mediated by P-Selectin Glycoprotein Ligand 1]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>532</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>524</prism:startingPage>
<prism:section>HOST DEFENSE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/533?rss=1">
<title><![CDATA[[HOST DEFENSE] In Vivo Lipopolysaccharide Exposure of Human Blood Leukocytes Induces Cross-Tolerance to Multiple TLR Ligands]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/533?rss=1</link>
<description><![CDATA[
<p>In vitro and in vivo experiments in mice have shown that exposure of cells to the TLR4 ligand LPS induces tolerance toward a second exposure to LPS and induces cross-tolerance to certain other TLR ligands. Recently, we found that LPS tolerance in experimental human endotoxemia and Gram-negative sepsis is associated with elevated levels of IL-1R-associated kinase M, an intracellular negative regulator of MyD88-dependent TLR signaling. In the present study, we investigated whether in vivo exposure of humans to LPS induces tolerance in circulating leukocytes to other TLR agonists that rely either on MyD88- dependent or on MyD88-independent signaling. Analysis of TNF, IL-1&beta;, IL-6, and IL-10 levels in whole blood demonstrated that leukocytes were hyporesponsive to ex vivo LPS restimulation 3&ndash;8 h after i.v. LPS injection (4 ng/kg). Reduced cytokine release during the same interval was also observed in whole blood further stimulated with MyD88-dependent ligands for TLR2, TLR5, and TLR7 or with whole bacteria. Strikingly, blood leukocytes were also tolerant to a ligand for TLR3, which signals solely through a MyD88-independent (Toll IL-1R domain-containing adaptor-inducing IFN-&beta; (TRIF)-dependent) pathway. The hyporesponsiveness of leukocytes to TLR3 ligation was associated with reduced rather than increased levels of the recently identified TRIF inhibitor SARM. Taken together, these data indicate that systemic LPS challenge of human volunteers induces cross-tolerance to multiple TLR ligands that signal in a MyD88-dependent or MyD88-independent manner and suggest that LPS exposure of human blood leukocytes may hamper the inflammatory response to various microbial components.</p>
]]></description>
<dc:creator><![CDATA[de Vos, A. F., Pater, J. M., van den Pangaart, P. S., de Kruif, M. D., van 't Veer, C., van der Poll, T.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802189</dc:identifier>
<dc:title><![CDATA[[HOST DEFENSE] In Vivo Lipopolysaccharide Exposure of Human Blood Leukocytes Induces Cross-Tolerance to Multiple TLR Ligands]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>542</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>533</prism:startingPage>
<prism:section>HOST DEFENSE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/543?rss=1">
<title><![CDATA[[HOST DEFENSE] LL-37 Complexation with Glycosaminoglycans in Cystic Fibrosis Lungs Inhibits Antimicrobial Activity, Which Can Be Restored by Hypertonic Saline]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/543?rss=1</link>
<description><![CDATA[
<p>There is an abundance of antimicrobial peptides in cystic fibrosis (CF) lungs. Despite this, individuals with CF are susceptible to microbial colonization and infection. In this study, we investigated the antimicrobial response within the CF lung, focusing on the human cathelicidin LL-37. We demonstrate the presence of the LL-37 precursor, human cathelicidin precursor protein designated 18-kDa cationic antimicrobial protein, in the CF lung along with evidence that it is processed to active LL-37 by proteinase-3. We demonstrate that despite supranormal levels of LL-37, the lung fluid from CF patients exhibits no demonstrable antimicrobial activity. Furthermore <I>Pseudomonas</I> killing by physiological concentrations of exogenous LL-37 is inhibited by CF bronchoalveolar lavage (BAL) fluid due to proteolytic degradation of LL-37 by neutrophil elastase and cathepsin D. The endogenous LL-37 in CF BAL fluid is protected from this proteolysis by interactions with glycosaminoglycans, but while this protects LL-37 from proteolysis it results in inactivation of LL-37 antimicrobial activity. By digesting glycosaminoglycans in CF BAL fluid, endogenous LL-37 is liberated and the antimicrobial properties of CF BAL fluid restored. High sodium concentrations also liberate LL-37 in CF BAL fluid in vitro. This is also seen in vivo in CF sputum where LL-37 is complexed to glycosaminoglycans but is liberated following nebulized hypertonic saline resulting in increased antimicrobial effect. These data suggest glycosaminoglycan&ndash;LL-37 complexes to be potential therapeutic targets. Factors that disrupt glycosaminoglycan&ndash;LL-37 aggregates promote the antimicrobial effects of LL-37 with the caveat that concomitant administration of antiproteases may be needed to protect the now liberated LL-37 from proteolytic cleavage.</p>
]]></description>
<dc:creator><![CDATA[Bergsson, G., Reeves, E. P., McNally, P., Chotirmall, S. H., Greene, C. M., Greally, P., Murphy, P., O'Neill, S. J., McElvaney, N. G.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803959</dc:identifier>
<dc:title><![CDATA[[HOST DEFENSE] LL-37 Complexation with Glycosaminoglycans in Cystic Fibrosis Lungs Inhibits Antimicrobial Activity, Which Can Be Restored by Hypertonic Saline]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>551</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>543</prism:startingPage>
<prism:section>HOST DEFENSE</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/552?rss=1">
<title><![CDATA[[INFLAMMATION] Cholinergic Neural Signals to the Spleen Down-Regulate Leukocyte Trafficking via CD11b]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/552?rss=1</link>
<description><![CDATA[
<p>The cholinergic anti-inflammatory pathway is a physiological mechanism that inhibits cytokine production and diminishes tissue injury during inflammation. Recent studies demonstrate that cholinergic signaling reduces adhesion molecule expression and chemokine production by endothelial cells and suppresses leukocyte migration during inflammation. It is unclear how vagus nerve stimulation regulates leukocyte trafficking because the vagus nerve does not innervate endothelial cells. Using mouse models of leukocyte trafficking, we show that the spleen, which is a major point of control for cholinergic modulation of cytokine production, is essential for vagus nerve-mediated regulation of neutrophil activation and migration. Administration of nicotine, a pharmacologic agonist of the cholinergic anti-inflammatory pathway, significantly reduces levels of CD11b, a &beta;<SUB>2</SUB>-integrin involved in cell adhesion and leukocyte chemotaxis, on the surface of neutrophils in a dose-dependent manner and this function requires the spleen. Similarly, vagus nerve stimulation significantly attenuates neutrophil surface CD11b levels only in the presence of an intact and innervated spleen. Further mechanistic studies reveal that nicotine suppresses F-actin polymerization, the rate-limiting step for CD11b surface expression. These studies demonstrate that modulation of leukocyte trafficking via cholinergic signaling to the spleen is a specific, centralized neural pathway positioned to suppress the excessive accumulation of neutrophils at inflammatory sites. Activating this mechanism may have important therapeutic potential for preventing tissue injury during inflammation.</p>
]]></description>
<dc:creator><![CDATA[Huston, J. M., Rosas-Ballina, M., Xue, X., Dowling, O., Ochani, K., Ochani, M., Yeboah, M. M., Chatterjee, P. K., Tracey, K. J., Metz, C. N.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802684</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] Cholinergic Neural Signals to the Spleen Down-Regulate Leukocyte Trafficking via CD11b]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>559</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>552</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/560?rss=1">
<title><![CDATA[[INFLAMMATION] Major Role of {gamma}{delta} T Cells in the Generation of IL-17+ Uveitogenic T Cells]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/560?rss=1</link>
<description><![CDATA[
<p>We show that in vitro activation of interphotoreceptor retinoid-binding protein (IRBP)-specific T cells from C57BL/6 mice immunized with an uveitogenic IRBP peptide (IRBP<SUB>1&ndash;20</SUB>) under TH17-polarizing conditions is associated with increased expansion of T cells expressing the  TCR. We also show that highly purified &beta; or  T cells from C57BL/6 mice immunized with IRBP<SUB>1&ndash;20</SUB> produced only small amounts of IL-17 after exposure to the immunizing Ag in vitro, whereas a mixture of the same T cells produced greatly increased amounts of IL-17. IRBP-induced T cells from IRBP-immunized TCR-<sup>&ndash;/&ndash;</sup> mice on the C57BL/6 genetic background produced significantly lower amounts of IL-17 than did wild-type C57BL/6 mice and had significantly decreased experimental autoimmune uveitis-inducing ability. However, reconstitution of the TCR-<sup>&ndash;/&ndash;</sup> mice before immunization with a small number of  T cells from IRBP-immunized C57BL/6 mice restored the disease-inducing capability of their IRBP-specific T cells and greatly enhanced the generation of IL-17<sup>+</sup> T cells in the recipient mice. Our study suggests that  T cells are important in the generation and activation of IL-17-producing autoreactive T cells and play a major role in the pathogenesis of experimental autoimmune uveitis.</p>
]]></description>
<dc:creator><![CDATA[Cui, Y., Shao, H., Lan, C., Nian, H., O'Brien, R. L., Born, W. K., Kaplan, H. J., Sun, D.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900241</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] Major Role of {gamma}{delta} T Cells in the Generation of IL-17+ Uveitogenic T Cells]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>567</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>560</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/568?rss=1">
<title><![CDATA[[INFLAMMATION] IRAK4 Kinase Activity Is Required for Th17 Differentiation and Th17-Mediated Disease]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/568?rss=1</link>
<description><![CDATA[
<p>Both IL-23- and IL-1-mediated signaling pathways play important roles in Th17 cell differentiation, cytokine production, and autoimmune diseases. The IL-1R-associated kinase 4 (IRAK4) is critical for IL-1/TLR signaling. We show here that inactivation of IRAK4 kinase in mice (IRAK4 KI) results in significant resistance to experimental autoimmune encephalomyelitis due to a reduction in infiltrating inflammatory cells into the CNS and reduced Ag-specific CD4<sup>+</sup> T cell-mediated IL-17 production. Adoptive transfer of myelin oligodendrocyte glycoprotein 35&ndash;55-specific IRAK4 KI Th17 cells failed to induce experimental autoimmune encephalomyelitis in either wild-type or IRAK4 KI recipient mice, indicating the lack of autoantigen-specific Th17 cell activities in the absence of IRAK4 kinase activity. Furthermore, the absence of IRAK4 kinase activity blocked induction of IL-23R expression, STAT3 activation by IL-23, and Th17 cytokine expression in differentiated Th17 cells. Importantly, blockade of IL-1 signaling by IL-1RA inhibited Th17 differentiation and IL-23-induced cytokine expression in differentiated Th17 cells. The results of these studies demonstrate that IL-1-mediated IRAK4 kinase activity in T cells is essential for induction of IL-23R expression, Th17 differentiation, and autoimmune disease.</p>
]]></description>
<dc:creator><![CDATA[Staschke, K. A., Dong, S., Saha, J., Zhao, J., Brooks, N. A., Hepburn, D. L., Xia, J., Gulen, M. F., Kang, Z., Altuntas, C. Z., Tuohy, V. K., Gilmour, R., Li, X., Na, S.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802361</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] IRAK4 Kinase Activity Is Required for Th17 Differentiation and Th17-Mediated Disease]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>577</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>568</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/578?rss=1">
<title><![CDATA[[INFLAMMATION] Differential Regulation of P2X7 Receptor Activation by Extracellular Nicotinamide Adenine Dinucleotide and Ecto-ADP-Ribosyltransferases in Murine Macrophages and T Cells]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/578?rss=1</link>
<description><![CDATA[
<p>Extracellular NAD induces the ATP-independent activation of the ionotropic P2X<SUB>7</SUB> purinergic receptor (P2X<SUB>7</SUB>R) in murine T lymphocytes via a novel covalent pathway involving ADP-ribosylation of arginine residues on the P2X<SUB>7</SUB>R ectodomain. This modification is catalyzed by ART2.2, a GPI-anchored ADP-ribosyltransferase (ART) that is constitutively expressed in murine T cells. We previously reported that ART2.1, a related ecto-ART, is up-regulated in inflammatory murine macrophages that constitutively express P2X<SUB>7</SUB>R. Thus, we tested the hypothesis that extracellular NAD acts via ART2.1 to regulate P2X<SUB>7</SUB>R function in murine macrophages. Coexpression of the cloned murine P2X<SUB>7</SUB>R with ART2.1 or ART2.2 in HEK293 cells verified that P2X<SUB>7</SUB>R is an equivalent substrate for ADP-ribosylation by either ART2.1 or ART2.2. However, in contrast with T cells, the stimulation of macrophages or HEK293 cells with NAD alone did not activate the P2X<SUB>7</SUB>R. Rather, NAD potentiated ATP-dependent P2X<SUB>7</SUB>R activation as indicated by a left shift in the ATP dose-response relationship. Thus, extracellular NAD regulates the P2X<SUB>7</SUB>R in both macrophages and T cells but via distinct mechanisms. Although ADP-ribosylation is sufficient to gate a P2X<SUB>7</SUB>R channel opening in T cells, this P2X<SUB>7</SUB>R modification in macrophages does not gate the channel but decreases the threshold for gating in response to ATP binding. These findings indicate that extracellular NAD and ATP can act synergistically to regulate P2X<SUB>7</SUB>R signaling in murine macrophages and also suggest that the cellular context in which P2X<SUB>7</SUB>R signaling occurs differs between myeloid and lymphoid leukocytes.</p>
]]></description>
<dc:creator><![CDATA[Hong, S., Schwarz, N., Brass, A., Seman, M., Haag, F., Koch-Nolte, F., Schilling, W. P., Dubyak, G. R.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900120</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] Differential Regulation of P2X7 Receptor Activation by Extracellular Nicotinamide Adenine Dinucleotide and Ecto-ADP-Ribosyltransferases in Murine Macrophages and T Cells]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>592</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>578</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/593?rss=1">
<title><![CDATA[[INFLAMMATION] Pleiotropic Roles of S100A12 in Coronary Atherosclerotic Plaque Formation and Rupture]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/593?rss=1</link>
<description><![CDATA[
<p>Macrophages, cytokines, and matrix metalloproteinases (MMP) play important roles in atherogenesis. The Ca<sup>2+</sup>-binding protein S100A12 regulates monocyte migration and may contribute to atherosclerosis by inducing proinflammatory cytokines in macrophages. We found significantly higher S100A12 levels in sera from patients with coronary artery disease than controls and levels correlated positively with C-reactive protein. S100A12 was released into the coronary circulation from ruptured plaque in acute coronary syndrome, and after mechanical disruption by percutaneous coronary intervention in stable coronary artery disease. In contrast to earlier studies, S100A12 did not stimulate proinflammatory cytokine production by human monocytes or macrophages. Similarly, no induction of MMP genes was found in macrophages stimulated with S100A12. Because S100A12 binds Zn<sup>2+</sup>, we studied some functional aspects that could modulate atherogenesis. S100A12 formed a hexamer in the presence of Zn<sup>2+</sup>; a novel Ab was generated that specifically recognized this complex. By chelating Zn<sup>2+</sup>, S100A12 significantly inhibited MMP-2, MMP-9, and MMP-3, and the Zn<sup>2+</sup>-induced S100A12 complex colocalized with these in foam cells in human atheroma. S100A12 may represent a new marker of this disease and may protect advanced atherosclerotic lesions from rupture by inhibiting excessive MMP-2 and MMP-9 activities by sequestering Zn<sup>2+</sup>.</p>
]]></description>
<dc:creator><![CDATA[Goyette, J., Yan, W. X., Yamen, E., Chung, Y. M., Lim, S. Y., Hsu, K., Rahimi, F., Di Girolamo, N., Song, C., Jessup, W., Kockx, M., Bobryshev, Y. V., Freedman, S. B., Geczy, C. L.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900373</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] Pleiotropic Roles of S100A12 in Coronary Atherosclerotic Plaque Formation and Rupture]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>603</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>593</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/604?rss=1">
<title><![CDATA[[INFLAMMATION] Pulmonary Eosinophils and Their Role in Immunopathologic Responses to Formalin-Inactivated Pneumonia Virus of Mice]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/604?rss=1</link>
<description><![CDATA[
<p>Enhanced disease is the term used to describe the aberrant Th2-skewed responses to naturally acquired human respiratory syncytial virus (hRSV) infection observed in individuals vaccinated with formalin-inactivated viral Ags. Here we explore this paradigm with pneumonia virus of mice (PVM), a pathogen that faithfully reproduces features of severe hRSV infection in a rodent host. We demonstrate that PVM infection in mice vaccinated with formalin-inactivated Ags from PVM-infected cells (PVM Ags) yields Th2-skewed hypersensitivity, analogous to that observed in response to hRSV. Specifically, we detect elevated levels of IL-4, IL-5, IL-13, and eosinophils in bronchoalveolar lavage fluid of PVM-infected mice that were vaccinated with PVM Ags, but not among mice vaccinated with formalin-inactivated Ags from uninfected cells (control Ags). Interestingly, infection in PVM Ag-vaccinated mice was associated with a ~10-fold reduction in lung virus titer and protection against weight loss when compared with infected mice vaccinated with control Ags, despite the absence of serum-neutralizing Abs. Given recent findings documenting a role for eosinophils in promoting clearance of hRSV in vivo, we explored the role of eosinophils in altering the pathogenesis of disease with eosinophil-deficient mice. We found that eosinophil deficiency had no impact on virus titer in PVM Ag-vaccinated mice, nor on weight loss or levels of CCL11 (eotaxin-1), IFN-, IL-5, or IL-13 in bronchoalveolar lavage fluid. However, levels of both IL-4 and CCL3 (macrophage inflammatory protein-1) in bronchoalveolar lavage fluid were markedly diminished in PVM Ag-vaccinated, PVM-infected eosinophil-deficient mice when compared with wild-type controls.</p>
]]></description>
<dc:creator><![CDATA[Percopo, C. M., Qiu, Z., Phipps, S., Foster, P. S., Domachowske, J. B., Rosenberg, H. F.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802270</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] Pulmonary Eosinophils and Their Role in Immunopathologic Responses to Formalin-Inactivated Pneumonia Virus of Mice]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>612</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>604</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/613?rss=1">
<title><![CDATA[[INFLAMMATION] IL-1R Signaling within the Central Nervous System Regulates CXCL12 Expression at the Blood-Brain Barrier and Disease Severity during Experimental Autoimmune Encephalomyelitis]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/613?rss=1</link>
<description><![CDATA[
<p>Multiple sclerosis (MS) is an autoimmune disease of the CNS characterized by disruption of the blood-brain barrier (BBB). This breach in CNS immune privilege allows undeterred trafficking of myelin-specific lymphocytes into the CNS where they induce demyelination. Although the mechanism of BBB compromise is not known, the chemokine CXCL12 has been implicated as a molecular component of the BBB whose pattern of expression is specifically altered during MS and which correlates with disease severity. The inflammatory cytokine IL-1&beta; has recently been shown to contribute not only to BBB permeability but also to the development of IL-17-driven autoimmune responses. Using experimental autoimmune encephalomyelitis, the rodent model of MS, we demonstrate that IL-1&beta; mediates pathologic relocation of CXCL12 during the induction phase of the disease, before the development of BBB disruption. We also show that CD4, CD8, and, surprisingly  T cells are all sources of IL-1&beta;. In addition,  T cells are also targets of this cytokine, contributing to IL-1&beta;-mediated production of IL-17. Finally, we show that the level of CNS IL-1R determines the clinical severity of experimental autoimmune encephalomyelitis. These data suggest that T cell-derived IL-1&beta; contributes to loss of immune privilege during CNS autoimmunity via pathologic alteration in the expression of CXCL12 at the BBB.</p>
]]></description>
<dc:creator><![CDATA[McCandless, E. E., Budde, M., Lees, J. R., Dorsey, D., Lyng, E., Klein, R. S.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802258</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] IL-1R Signaling within the Central Nervous System Regulates CXCL12 Expression at the Blood-Brain Barrier and Disease Severity during Experimental Autoimmune Encephalomyelitis]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>620</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>613</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/621?rss=1">
<title><![CDATA[[INFLAMMATION] The Presumed Hyporesponsive Behavior of Rheumatoid Arthritis T Lymphocytes Can Be Attributed to Spontaneous Ex Vivo Apoptosis rather than Defects in T Cell Receptor Signaling]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/621?rss=1</link>
<description><![CDATA[
<p>Genetic associations and the clinical success of compounds targeting TCR costimulatory proteins suggest an active role for TCR signaling in the initiation and perpetuation of rheumatoid arthritis (RA). Paradoxically, T cells isolated from affected joints in RA show impaired proliferative and cytokine responses following stimulation with mitogens and recall Ags attributed in part to chronic T cell exposure to oxidative stress and inflammatory cytokines. Therefore, it is uncertain how local autoreactive TCR signaling contributes to pathology in established RA. Using single-cell analysis, we show that in contrast to results obtained in bulk culture assays, T cells from the synovial fluid of RA patients proliferate and produce cytokines (IL-2, TNF-, and IFN-) as efficiently, if not more so, than T cells isolated from healthy donors and RA patient peripheral blood following TCR/CD28 stimulation. RA synovial fluid T cell hyporesponsiveness observed in bulk cultures can be attributed to spontaneous apoptosis ex vivo, which is associated with altered ratios of proapoptotic Noxa and anti-apoptotic Mcl-1 expression. The absence of RA synovial T cell proliferation and cytokine production in situ, despite the capacity of these cells to support productive TCR signaling, suggests that T cells contribute to local pathology in established RA by TCR-independent mechanisms.</p>
]]></description>
<dc:creator><![CDATA[Abreu, J. R. F., Grabiec, A. M., Krausz, S., Spijker, R., Burakowski, T., Maslinski, W., Eldering, E., Tak, P. P., Reedquist, K. A.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803278</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] The Presumed Hyporesponsive Behavior of Rheumatoid Arthritis T Lymphocytes Can Be Attributed to Spontaneous Ex Vivo Apoptosis rather than Defects in T Cell Receptor Signaling]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>630</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>621</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/631?rss=1">
<title><![CDATA[[INFLAMMATION] Aberrant Tissue Localization of Fungus-Specific CD4+ T Cells in IL-10-Deficient Mice]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/631?rss=1</link>
<description><![CDATA[
<p><I>Aspergillus fumigatus</I>, a common environmental fungus, can cause lethal invasive infections in immunocompromised hosts. In immunocompetent individuals, however, inhaled <I>A. fumigatus</I> spores prime CD4<sup>+</sup> T cells and activate immune responses that prevent invasive infection. Calibration of inflammatory responses to levels that prevent fungal invasion without inducing collateral tissue damage is essential for host survival, but the underlying regulatory mechanisms remain undefined. Although IL-10 is a validated regulatory cytokine that suppresses immune responses, and IL-10 deficiency or blockade generally enhances immune responses, we find that <I>A. fumigatus</I>-specific T cell frequencies are markedly reduced in airways of IL-10-deficient mice. T cell priming, proliferation, and survival were unaffected by IL-10 deficiency and did not account for decreased frequencies of <I>A. fumigatus</I>-specific T cells in the airways of IL-10-deficient mice. Instead, IL-10 deficiency results in redistribution of <I>A. fumigatus</I>-specific T cells from infected lungs to the gut, a process that is reversed by antibiotic-mediated depletion of intestinal microbes. Our studies demonstrate that disregulated immune responses in the gut can result in dramatic redistribution of pathogen-specific T cells within the host.</p>
]]></description>
<dc:creator><![CDATA[Rivera, A., Collins, N., Stephan, M. T., Lipuma, L., Leiner, I., Pamer, E. G.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900396</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] Aberrant Tissue Localization of Fungus-Specific CD4+ T Cells in IL-10-Deficient Mice]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>641</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>631</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/642?rss=1">
<title><![CDATA[[INFLAMMATION] T-bet Knockout Prevents Helicobacter felis-Induced Gastric Cancer]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/642?rss=1</link>
<description><![CDATA[
<p><I>Helicobacter</I> infection is the primary risk factor for gastric cancer, with the cytokine environment within the gastric mucosa the strongest predictor of disease risk. Elevated TNF-, IL-1&beta;, and low IL-10 are associated with the highest risk. In this study, we used C57BL/6 mice to identify T-bet as a central regulator of the cytokine environment during <I>Helicobacter felis</I> infection. We infected male and female C57BL/6 and C57BL/6-T-bet knockout (KO) liter mates with <I>H. felis</I> and examined the bacterial colonization, immune response, and mucosal damage at varying time points. T-bet KO mice maintained infection for 15 mo at similar levels to wild-type mice. Infection and immune response did not differ between male and female mice. Despite sustained infection, T-bet KO mice respond with a blunted Th1 response associated with preservation of parietal and chief cells and protection from the development of gastric cancer. Unexpectedly, T-bet KO mice develop a gastric environment that would not be expected based on the phenotype of T-bet KO CD4 cells alone. T-bet KO mice respond to <I>H. felis</I> infection with a markedly blunted IL-1&beta; and TNF- and elevated IL-10 levels. Activity of this one master regulator modulates the expression of the key gastric mucosal cytokines associated with gastric cancer and may be a target for therapy to restore immune balance clinically in patients at risk for gastric cancer.</p>
]]></description>
<dc:creator><![CDATA[Stoicov, C., Fan, X., Liu, J. H., Bowen, G., Whary, M., Kurt-Jones, E., Houghton, J.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900511</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] T-bet Knockout Prevents Helicobacter felis-Induced Gastric Cancer]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>649</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>642</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/650?rss=1">
<title><![CDATA[[INFLAMMATION] Fusion Loop Peptide of the West Nile Virus Envelope Protein Is Essential for Pathogenesis and Is Recognized by a Therapeutic Cross-Reactive Human Monoclonal Antibody]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/650?rss=1</link>
<description><![CDATA[
<p>West Nile virus is an emerging pathogen that can cause fatal neurological disease. A recombinant human mAb, mAb11, has been described as a candidate for the prevention and treatment of West Nile disease. Using a yeast surface display epitope mapping assay and neutralization escape mutant, we show that mAb11 recognizes the fusion loop, at the distal end of domain II of the West Nile virus envelope protein. Ab mAb11 cross-reacts with all four dengue viruses and provides protection against dengue (serotypes 2 and 4) viruses. In contrast to the parental West Nile virus, a neutralization escape variant failed to cause lethal encephalitis (at higher infectious doses) or induce the inflammatory responses associated with blood-brain barrier permeability in mice, suggesting an important role for the fusion loop in viral pathogenesis. Our data demonstrate that an intact West Nile virus fusion loop is critical for virulence, and that human mAb11 targeting this region is efficacious against West Nile virus infection. These experiments define the molecular determinant on the envelope protein recognized by mAb11 and demonstrate the importance of this region in causing West Nile encephalitis.</p>
]]></description>
<dc:creator><![CDATA[Sultana, H., Foellmer, H. G., Neelakanta, G., Oliphant, T., Engle, M., Ledizet, M., Krishnan, M. N., Bonafe, N., Anthony, K. G., Marasco, W. A., Kaplan, P., Montgomery, R. R., Diamond, M. S., Koski, R. A., Fikrig, E.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900093</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] Fusion Loop Peptide of the West Nile Virus Envelope Protein Is Essential for Pathogenesis and Is Recognized by a Therapeutic Cross-Reactive Human Monoclonal Antibody]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>660</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>650</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/661?rss=1">
<title><![CDATA[[INFLAMMATION] Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/661?rss=1</link>
<description><![CDATA[
<p>Antiretroviral therapy (ART) shows variable blood-brain barrier penetration. This may affect the development of neurological complications of HIV infection. In attempts to attenuate viral growth for the nervous system, cell-based nanoformulations were developed with the focus on improving drug pharmacokinetics. We reasoned that ART carriage could be facilitated within blood-borne macrophages traveling across the blood-brain barrier. To test this idea, an HIV-1 encephalitis (HIVE) rodent model was used where HIV-1-infected human monocyte-derived macrophages were stereotactically injected into the subcortex of severe combined immunodeficient mice. ART was prepared using indinavir (IDV) nanoparticles (NP, nanoART) loaded into murine bone marrow macrophages (BMM, IDV-NP-BMM) after ex vivo cultivation. IDV-NP-BMM was administered i.v. to mice resulting in continuous IDV release for 14 days. Rhodamine-labeled IDV-NP was readily observed in areas of HIVE and specifically in brain subregions with active astrogliosis, microgliosis, and neuronal loss. IDV-NP-BMM treatment led to robust IDV levels and reduced HIV-1 replication in HIVE brain regions. We conclude that nanoART targeting to diseased brain through macrophage carriage is possible and can be considered in developmental therapeutics for HIV-associated neurological disease.</p>
]]></description>
<dc:creator><![CDATA[Dou, H., Grotepas, C. B., McMillan, J. M., Destache, C. J., Chaubal, M., Werling, J., Kipp, J., Rabinow, B., Gendelman, H. E.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900274</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>669</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>661</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/670?rss=1">
<title><![CDATA[[INFLAMMATION] Lack of MyD88 Protects the Immunodeficient Host Against Fatal Lung Inflammation Triggered by the Opportunistic Bacteria Burkholderia cenocepacia]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/670?rss=1</link>
<description><![CDATA[
<p><I>Burkholderia cenocepacia</I> is an opportunistic pathogen of major concern for cystic fibrosis patients as well as immunocompromised cancer patients and transplant recipients. The mechanisms by which <I>B. cenocepacia</I> triggers a rapid health deterioration of the susceptible host have yet to be characterized. TLR and their key signaling intermediate MyD88 play a central role in the detection of microbial molecular patterns and in the initiation of an effective immune response. We performed a study to better understand the role of TLR-MyD88 signaling in <I>B. cenocepacia</I>-induced pathogenesis in the immunocompromised host, using an experimental murine model. The time-course of several dynamic parameters, including animal survival, bacterial load, and secretion of critical inflammatory mediators, was compared in infected and immunosuppressed wild-type and <I>MyD88</I><sup>&ndash;/&ndash;</sup> mice. Notably, when compared with wild-type mice, infected <I>MyD88</I><sup>&ndash;/&ndash;</sup> animals displayed significantly reduced levels of inflammatory mediators (including KC, TNF-, IL-6, MIP-2, and G-CSF) in blood and lung airspaces. Moreover, despite a higher transient bacterial load in the lungs, immunosuppressed mice deficient in MyD88 had an unexpected survival advantage. Finally, we showed that this <I>B. cenocepacia</I>-induced life-threatening infection of wild-type mice involved the proinflammatory cytokine TNF- and could be prevented by corticosteroids. Altogether, our findings demonstrate that a MyD88-dependent pathway can critically contribute to a detrimental host inflammatory response that leads to fatal pneumonia.</p>
]]></description>
<dc:creator><![CDATA[Ventura, G. M. d. C., Balloy, V., Ramphal, R., Khun, H., Huerre, M., Ryffel, B., Plotkowski, M.-C. M., Chignard, M., Si-Tahar, M.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0801497</dc:identifier>
<dc:title><![CDATA[[INFLAMMATION] Lack of MyD88 Protects the Immunodeficient Host Against Fatal Lung Inflammation Triggered by the Opportunistic Bacteria Burkholderia cenocepacia]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>676</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>670</prism:startingPage>
<prism:section>INFLAMMATION</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/677?rss=1">
<title><![CDATA[[CLINICAL IMMUNOLOGY] Evidence for the Specificity for Platelet HPA-1a Alloepitope and the Presenting HLA-DR52a of Diverse Antigen-Specific Helper T Cell Clones from Alloimmunized Mothers]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/677?rss=1</link>
<description><![CDATA[
<p>Maternal alloantibodies against the human platelet Ag (HPA)-1a allotype of the platelet &beta;<SUB>3</SUB> integrin GpIIb/IIIa can cause severe fetal or neonatal hemorrhage. Almost all anti-HPA-1a-immune mothers are homozygous for HPA-1b and carry HLA-DR52a (DRB3*0101). The single Pro<sup>33</sup> -&gt;Leu substitution (HPA-1b-&gt;HPA-1a) was previously predicted to create a binding motif for HLA-DR52a that can lead to alloimmunization. We have isolated six CD4<sup>+</sup> T cell clones from three such mothers, which all respond to intact HPA-1a<sup>+</sup>, but not HPA-1b<sup>+</sup>, platelets. We used them to define the "core" and "anchor" residues of this natural T cell epitope. Molecular modeling based on a recently published crystal structure can explain the preferential presentation of the Leu<sup>33</sup> (but not Pro<sup>33</sup> variant) by HLA-DR52a rather than the linked HLA-DR3 or the allelic DR52b. The modeling also predicts efficient anchoring at position 33 by several alternative hydrophobic -amino acids; indeed, a recently identified variant with Val<sup>33</sup> is presented well to two clones, and is therefore potentially alloimmunogenic. Finally, these HPA-1a-specific T cell clones use a variety of T cell receptors, but all have a "Th1" (IFN--producing) profile and are suitable for testing selective immunotherapies that might be applicable in vivo.</p>
]]></description>
<dc:creator><![CDATA[Rayment, R., Kooij, T. W., Zhang, W., Siebold, C., Murphy, M. F., Allen, D., Willcox, N., Roberts, D. J.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0801473</dc:identifier>
<dc:title><![CDATA[[CLINICAL IMMUNOLOGY] Evidence for the Specificity for Platelet HPA-1a Alloepitope and the Presenting HLA-DR52a of Diverse Antigen-Specific Helper T Cell Clones from Alloimmunized Mothers]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>686</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>677</prism:startingPage>
<prism:section>CLINICAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/687?rss=1">
<title><![CDATA[[CLINICAL IMMUNOLOGY] Expression of IL-24, an Activator of the JAK1/STAT3/SOCS3 Cascade, Is Enhanced in Inflammatory Bowel Disease]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/687?rss=1</link>
<description><![CDATA[
<p>IL-24 is a member of the IL-10 family of cytokines. In this study, we investigated IL-24 expression in the inflamed mucosa of patients with inflammatory bowel disease (IBD), and characterized the molecular mechanisms responsible for IL-24 expression in human colonic subepithelial myofibroblasts (SEMFs). IL-24 expression in the IBD mucosa was evaluated by immunohistochemical methods. IL-24 mRNA and protein expression was determined by real-time PCR and ELISA, respectively. AP-1 and C/EBP DNA-binding activity and IL-24 promoter activity were assessed by EMSA analysis and a reporter gene assay, respectively. IL-24 mRNA expression was significantly elevated in active lesions from patients who have ulcerative colitis and Crohn&rsquo;s disease. Colonic SEMFs were identified as a major source of IL-24 in the mucosa. IL-1&beta;, but not IL-17A, TNF-, or IFN-, significantly enhanced IL-24 mRNA and protein expression in isolated colonic SEMFs. The IL-1&beta;-induced IL-24 mRNA expression was mediated by the activation of the transcription factors, AP-1 and C/EBP-&beta;. Induction of IL-24 mRNA stabilization was also involved in the effects of IL-1&beta;. IL-24 induced JAK1/STAT-3 phosphorylation and SOCS3 expression in HT-29 colonic epithelial cells. IL-24 did not modulate the proliferation of HT-29 cells, but significantly increased the mRNA expression of membrane-bound mucins (MUC1, MUC3, and MUC4). IL-24 derived from colonic SEMFs acts on colonic epithelial cells to elicit JAK1/STAT-3 activation and the expression of SOCS3 and mucins, supporting their suppressive effects on mucosal inflammation in IBD.</p>
]]></description>
<dc:creator><![CDATA[Andoh, A., Shioya, M., Nishida, A., Bamba, S., Tsujikawa, T., Kim-Mitsuyama, S., Fujiyama, Y.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0804169</dc:identifier>
<dc:title><![CDATA[[CLINICAL IMMUNOLOGY] Expression of IL-24, an Activator of the JAK1/STAT3/SOCS3 Cascade, Is Enhanced in Inflammatory Bowel Disease]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>695</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>687</prism:startingPage>
<prism:section>CLINICAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/696?rss=1">
<title><![CDATA[[CLINICAL IMMUNOLOGY] Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/696?rss=1</link>
<description><![CDATA[
<p>Previous work done in our laboratory, using mouse models, showed that soluble Fas ligand (sFasL) can efficiently delete donor anti-host T cells during their activation against irradiated host cells in MLCs. In the mouse models, this ex vivo sFasL treatment abrogated graft-vs-host disease (GVHD) while sparing donor T cells with antitumor reactivity. The present work was performed with human cells, to extend our work toward reduction of clinical GVHD. PBMC responders from a given individual (first party) were stimulated in vitro with irradiated PBMC stimulators from a second person (second party), in the presence of sFasL. In control MLCs without sFasL, alloreacting T cells began to up-regulate Fas (CD95) detectably and became sensitive to Fas-mediated apoptosis by as early as day 1&ndash;2. In MLCs containing sFasL, there were greatly reduced numbers of alloreacting CD3<sup>+</sup>CFSE<sup>lo</sup> cells, activation Ag-expressing CD4<sup>hi</sup> and CD8<sup>hi</sup> cells, IFN--producing CD4<sup>+</sup> and CD8<sup>+</sup> cells, and CD8<sup>+</sup>CD107a<sup>+</sup> CTLs. Furthermore, mice transplanted with the ex vivo sFasL/MLR-treated cells had prolonged time to fatal GVHD in an in vivo xenogeneic GVHD model. Responder cells harvested from primary MLCs containing sFasL had reduced proliferation in response to second party cells, but proliferated in response to CMV Ags, PHA, and third party cells. In addition, sFasL/MLR-treated cell populations contained influenza-specific T cells, CD4<sup>+</sup>FOXP3<sup>+</sup> T cells, and CD4<sup>+</sup>CD25<sup>+</sup> T cells. These data indicate that this ex vivo sFasL/MLR depletion of alloreacting human donor anti-host T cells was efficient and selective.</p>
]]></description>
<dc:creator><![CDATA[Bohana-Kashtan, O., Morisot, S., Hildreth, R., Brayton, C., Levitsky, H. I., Civin, C. I.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0800561</dc:identifier>
<dc:title><![CDATA[[CLINICAL IMMUNOLOGY] Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>705</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>696</prism:startingPage>
<prism:section>CLINICAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/706?rss=1">
<title><![CDATA[[CLINICAL IMMUNOLOGY] Vaccine-Induced, Simian Immunodeficiency Virus-Specific CD8+ T Cells Reduce Virus Replication but Do Not Protect from Simian Immunodeficiency Virus Disease Progression]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/706?rss=1</link>
<description><![CDATA[
<p>Our limited understanding of the interaction between primate lentiviruses and the host immune system complicates the design of an effective HIV/AIDS vaccine. To identify immunological correlates of protection from SIV disease progression, we immunized two groups of five rhesus macaques (RMs) with either modified vaccinia Ankara (MVA) or MVA<I>udg</I> vectors that expressed SIVmac239 Gag and Tat. Both vectors raised a SIV-specific CD8<sup>+</sup> T cell response, with a magnitude that was greater in mucosal tissues than in peripheral blood. After challenge with SIVmac239, all vaccinated RMs showed mucosal and systemic CD8<sup>+</sup> T cell recall responses that appeared faster and were of greater magnitude than those in five unvaccinated control animals. All vaccinated RMs showed a ~1-log lower peak and early set-point SIV viral load than the unvaccinated animals, and then, by 8 wk postchallenge, exhibited levels of viremia similar to the controls. We observed a significant direct correlation between the magnitude of postchallenge SIV-specific CD8<sup>+</sup> T cell responses and SIV viral load. However, vaccinated RMs showed no protection from either systemic or mucosal CD4<sup>+</sup> T cell depletion and no improved survival. The observation that vaccine-induced, SIV-specific CD8<sup>+</sup> T cells that partially control SIVmac239 virus replication fail to protect from immunological or clinical progression of SIV infection underscores both the complexity of AIDS pathogenesis and the challenges of properly assessing the efficacy of candidate AIDS vaccines.</p>
]]></description>
<dc:creator><![CDATA[Engram, J. C., Dunham, R. M., Makedonas, G., Vanderford, T. H., Sumpter, B., Klatt, N. R., Ratcliffe, S. J., Garg, S., Paiardini, M., McQuoid, M., Altman, J. D., Staprans, S. I., Betts, M. R., Garber, D. A., Feinberg, M. B., Silvestri, G.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803746</dc:identifier>
<dc:title><![CDATA[[CLINICAL IMMUNOLOGY] Vaccine-Induced, Simian Immunodeficiency Virus-Specific CD8+ T Cells Reduce Virus Replication but Do Not Protect from Simian Immunodeficiency Virus Disease Progression]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>717</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>706</prism:startingPage>
<prism:section>CLINICAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/718?rss=1">
<title><![CDATA[[CLINICAL IMMUNOLOGY] Tuberculosis Is Associated with a Down-Modulatory Lung Immune Response That Impairs Th1-Type Immunity]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/718?rss=1</link>
<description><![CDATA[
<p>Immune mediators associated with human tuberculosis (TB) remain poorly defined. This study quantified levels of lung immune mediator gene expression at the time of diagnosis and during anti-TB treatment using cells obtained by induced sputum. Upon comparison to patients with other infectious lung diseases and volunteers, active pulmonary TB cases expressed significantly higher levels of mediators that counteract Th1-type and innate immunity. Despite the concomitant heightened levels of Th1-type mediators, immune activation may be rendered ineffectual by high levels of intracellular (SOCS and IRAK-M) and extracellular (IL-10 and TGF-&beta;RII, IL-1Rn, and IDO) immune suppressive mediators. These modulators are a direct response to <I>Mycobacterium tuberculosis</I> as, by day 30 of anti-TB treatment, many suppressive factors declined to that of controls whereas most Th1-type and innate immune mediators rose above pretreatment levels. Challenge of human immune cells with <I>M. tuberculosis</I> in vitro up-regulated these immune modulators as well. The observed low levels of NO synthase-2 produced by alveolar macrophages at TB diagnosis, along with the heightened amounts of suppressive mediators, support the conclusion that <I>M. tuberculosis</I> actively promotes down-modulatory mediators to counteract Th1-type and innate immunity as an immunopathological strategy. Our data highlight the potential application of immune mediators as surrogate markers for TB diagnosis or treatment response.</p>
]]></description>
<dc:creator><![CDATA[Almeida, A. S., Lago, P. M., Boechat, N., Huard, R. C., Lazzarini, L. C. O., Santos, A. R., Nociari, M., Zhu, H., Perez-Sweeney, B. M., Bang, H., Ni, Q., Huang, J., Gibson, A. L., Flores, V. C., Pecanha, L. R., Kritski, A. L., Lapa e Silva, J. R., Ho, J. L.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0801212</dc:identifier>
<dc:title><![CDATA[[CLINICAL IMMUNOLOGY] Tuberculosis Is Associated with a Down-Modulatory Lung Immune Response That Impairs Th1-Type Immunity]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>731</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>718</prism:startingPage>
<prism:section>CLINICAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/732?rss=1">
<title><![CDATA[[CLINICAL IMMUNOLOGY] A Novel Recombinant Fusion Protein Encoding a 20-Amino Acid Residue of the Third Extracellular (E3) Domain of CCR2 Neutralizes the Biological Activity of CCL2]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/732?rss=1</link>
<description><![CDATA[
<p>CCL2 is a key CC chemokine that has been implicated in a variety of inflammatory autoimmune diseases and in tumor progression and it is therefore an important target for therapeutic intervention in these diseases. Soluble receptor-based therapy is a known approach for neutralizing the in vivo functions of soluble mediators. Owing to the complexity of seven-transmembrane G protein-coupled receptors, efforts to generate neutralizing soluble chemokine receptors have so far failed. We developed a strategy that is based on the generation of short recombinant proteins encoding different segments of a G protein-coupled receptor, and tested the ability of each of them to bind and neutralize its target chemokine. We show that a fusion protein comprised of as few as 20 aa of the third extracellular (E3) domain of the CCL2 receptor, stabilized by the IgG H chain Fc domain (E3-IgG or BL-2030), selectively binds CCL2 and CCL16 and effectively neutralizes their biological activities. More importantly, E3-IgG (BL-2030) could effectively suppress the in vivo biological activity of CCL2, attenuating ongoing experimental autoimmune encephalomyelitis, as well as the development of human prostate tumor in SCID mice.</p>
]]></description>
<dc:creator><![CDATA[Izhak, L., Wildbaum, G., Zohar, Y., Anunu, R., Klapper, L., Elkeles, A., Seagal, J., Yefenof, E., Ayalon-Soffer, M., Karin, N.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0802746</dc:identifier>
<dc:title><![CDATA[[CLINICAL IMMUNOLOGY] A Novel Recombinant Fusion Protein Encoding a 20-Amino Acid Residue of the Third Extracellular (E3) Domain of CCR2 Neutralizes the Biological Activity of CCL2]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>739</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>732</prism:startingPage>
<prism:section>CLINICAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/740?rss=1">
<title><![CDATA[[CLINICAL IMMUNOLOGY] Coexpression of IL-18 Strongly Attenuates IL-12-Induced Systemic Toxicity through a Rapid Induction of IL-10 without Affecting its Antitumor Capacity]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/740?rss=1</link>
<description><![CDATA[
<p>IL-12 is an excellent candidate for the treatment of cancer due to its ability to drive strong antitumor responses. Recombinant IL-12 protein is currently used in cancer patients; however, systemic expression of rIL-12 presents disadvantages including cost and dose limitation due to its toxicity. In this study, we used hydrodynamic shear of cDNA as a tool to achieve systemic expression of IL-12. We found that sustained but toxic levels of serum IL-12 could be generated in 6- to 7-wk-old B6 mice after a single injection of the cDNA. Unexpectedly, we observed that when IL-12 cDNA is coinjected with IL-18 cDNA, IL-12 antitumor activity was maintained, but there was a significant attenuation of IL-12 toxicity, as evidenced by a greater survival index and a diminution of liver enzymes (ALT and AST). Interestingly, after IL-12 plus IL-18 cDNA administration, more rapid and higher IL-10 levels were observed than after IL-12 cDNA treatment alone. To understand the mechanism of protection, we coinjected IL-12 plus IL-10 cDNAs and observed an increase in survival that correlated with diminished serum levels of the inflammatory cytokines TNF- and IFN-. Confirming the protective role of early IL-10 expression, we observed a significant decrease in survival in IL-10 knockout mice or IL-10R-blocked B6 mice after IL-12 plus IL-18 treatment. Thus, our data demonstrate that the high and early IL-10 expression induced after IL-12 plus IL-18 cDNA treatment is critical to rapidly attenuate IL-12 toxicity without affecting its antitumor capacity. These data could highly contribute to the design of more efficient/less toxic protocols for the treatment of cancer.</p>
]]></description>
<dc:creator><![CDATA[Rodriguez-Galan, M. C., Reynolds, D., Correa, S. G., Iribarren, P., Watanabe, M., Young, H. A.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0804166</dc:identifier>
<dc:title><![CDATA[[CLINICAL IMMUNOLOGY] Coexpression of IL-18 Strongly Attenuates IL-12-Induced Systemic Toxicity through a Rapid Induction of IL-10 without Affecting its Antitumor Capacity]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>748</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>740</prism:startingPage>
<prism:section>CLINICAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/749?rss=1">
<title><![CDATA[[CLINICAL IMMUNOLOGY] Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/749?rss=1</link>
<description><![CDATA[
<p>The CD20 mAb ofatumumab (OFA) is more effective than rituximab (RTX) in promoting complement-dependent cytotoxicity (CDC) of B cells via the classical pathway (CP) of complement. CP activation is initiated by C1q binding to cell-bound IgG. Therefore, we examined the role of C1q in the dynamics of complement activation and CDC of B cell lines and primary cells from patients with chronic lymphocytic leukemia, reacted with OFA or RTX. C1q binding, complement activation, and colocalization of C1q with cell-bound mAbs were determined by flow cytometry and high-resolution digital imaging. C1q binds avidly to OFA-opsonized Raji and Daudi cells (<I>K</I><SUB>D</SUB> = 12&ndash;16 nM) and colocalizes substantially with cell-bound OFA. Cells opsonized with OFA undergo high levels of complement activation and CDC in C1q-depleted serum supplemented with low concentrations of C1q. Under comparable conditions, RTX-opsonized cells bind less C1q; in addition, even when higher concentrations of C1q are used to achieve comparable C1q binding to RTX-opsonized cells, less complement activation and CDC are observed. Greater CDC induced by OFA may occur because C1q is bound in close proximity and with high avidity to OFA, resulting in effective CP activation. Moreover, OFA binds to the small, extracellular CD20 loop, placing the mAb considerably closer to the cell membrane than does RTX. This may facilitate effective capture and concentration of activated complement components closer to the cell membrane, potentially shielding them from inactivation by fluid phase agents and promoting efficient generation of the membrane attack complex.</p>
]]></description>
<dc:creator><![CDATA[Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G. J., Parren, P. W. H. I., Taylor, R. P.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0900632</dc:identifier>
<dc:title><![CDATA[[CLINICAL IMMUNOLOGY] Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>758</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>749</prism:startingPage>
<prism:section>CLINICAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/759?rss=1">
<title><![CDATA[[CLINICAL IMMUNOLOGY] Systemic Reduction of Functionally Suppressive CD4dimCD25highFoxp3+ Tregs in Human Second Trimester Pregnancy Is Induced by Progesterone and 17{beta}-Estradiol]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/759?rss=1</link>
<description><![CDATA[
<p>CD4<sup>+</sup>CD25<sup>high</sup> regulatory T cells (Tregs) are implicated in the maintenance of murine pregnancy. However, reports regarding circulating Treg frequencies in human pregnancy are inconsistent, and the functionality and phenotype of these cells in pregnancy have not been clarified. The aim of this study was to determine the frequency, phenotype, and function of circulating Tregs in the second trimester of human pregnancy and the influence of progesterone and 17&beta;-estradiol on Treg phenotype and frequency. Based on expressions of Foxp3, CD127, and HLA-DR as determined by multicolor flow cytometry, we defined a proper CD4<sup>dim</sup>CD25<sup>high</sup> Treg population and showed, in contrast to most previous reports, that this population was reduced in second trimester of pregnancy. Unexpectedly, Foxp3 expression was decreased in the Treg, as well as in the CD4<sup>+</sup> population. These changes could be replicated in an in vitro system resembling the pregnancy hormonal milieu, where 17&beta;-estradiol, and in particular progesterone, induced, in line with the pregnancy situation, a reduction of CD4<sup>dim</sup>CD25<sup>high</sup>Foxp3<sup>+</sup> cells in PBMC from nonpregnant women. By coculturing FACS-sorted Tregs and autologous CD4<sup>+</sup>CD25<sup>&ndash;</sup> responder cells, we showed that Tregs from pregnant women still displayed the same suppressive capacity as nonpregnant women in terms of suppressing IL-2, TNF-, and IFN- secretion from responder cells while efficiently producing IL-4 and IL-10. Our findings support the view of hormones, particularly progesterone, as critical regulators of Tregs in pregnancy. Furthermore, we suggest that in the light of the results of this study, early data on circulating Treg frequencies in pregnancy need reevaluation.</p>
]]></description>
<dc:creator><![CDATA[Mjosberg, J., Svensson, J., Johansson, E., Hellstrom, L., Casas, R., Jenmalm, M. C., Boij, R., Matthiesen, L., Jonsson, J.-I., Berg, G., Ernerudh, J.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0803654</dc:identifier>
<dc:title><![CDATA[[CLINICAL IMMUNOLOGY] Systemic Reduction of Functionally Suppressive CD4dimCD25highFoxp3+ Tregs in Human Second Trimester Pregnancy Is Induced by Progesterone and 17{beta}-Estradiol]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>769</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>759</prism:startingPage>
<prism:section>CLINICAL IMMUNOLOGY</prism:section>
</item>

<item rdf:about="http://www.jimmunol.org/cgi/content/short/183/1/770?rss=1">
<title><![CDATA[[CORRECTIONS] The cyclic AMP response element modulator {alpha} suppresses CD86 expression and APC function]]></title>
<link>http://www.jimmunol.org/cgi/content/short/183/1/770?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Ahlmann, M., Varga, G., Sturm, K., Lippe, R., Benedyk, K., Viemann, D., Scholzen, T., Ehrchen, J., Muller, F. U., Seidl, M., Matus, M., Tsokos, G. C., Roth, J., Tenbrock, K.]]></dc:creator>
<dc:date>2009-06-19</dc:date>
<dc:identifier>info:doi/10.4049/jimmunol.0990045</dc:identifier>
<dc:title><![CDATA[[CORRECTIONS] The cyclic AMP response element modulator {alpha} suppresses CD86 expression and APC function]]></dc:title>
<dc:publisher>American Association of Immunologists</dc:publisher>
<prism:number>1</prism:number>
<prism:volume>183</prism:volume>
<prism:endingPage>770</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>770</prism:startingPage>
<prism:section>CORRECTIONS</prism:section>
</item>

</rdf:RDF>